Catatonia

Psychiatric MONDO:0800105 Pathograph 19 Show in embeddings browser Mental Health Disorder Psychomotor Disorder

Catatonia is a transdiagnostic psychomotor syndrome that arises across psychiatric, neurologic, neurodevelopmental, autoimmune, and general medical conditions rather than belonging to any one of them. It is defined clinically by a cluster of motor, volitional, affective, and behavioral signs — stupor, mutism, catalepsy and posturing, negativism, stereotypy, echolalia, grimacing, and agitation — and it is internally heterogeneous, with hypokinetic, hyperkinetic, and aberrant-volitional components that may overlap within a single episode. The mechanism is best described as convergence rather than as a single causal chain. Diverse upstream liabilities — a psychiatric illness, autoimmune encephalitis, a metabolic derangement, or exposure to and withdrawal from dopamine-blocking drugs — destabilize a shared set of psychomotor networks (cortico-striatal-thalamic, cortico-cerebellar, orbitofrontal, cingulate, and motor-premotor). Neurochemically, the best-evidenced disturbances are a cortical GABA-A receptor deficit (the direct correlate of the syndrome's near-immediate response to lorazepam), reduced striatal dopaminergic transmission, and glutamatergic/NMDA-mediated dysfunction, with immune mechanisms specifically relevant in autoimmune subgroups. Importantly, no single biomarker or unified mechanism accounts for catatonia across all contexts, and this entry models that heterogeneity explicitly as competing and complementary hypotheses rather than collapsing it into one chain. Treatment is unusually mechanism-legible for a psychiatric syndrome: benzodiazepines (lorazepam) and electroconvulsive therapy are both first-line and both act on the nodes curated here. Malignant catatonia — the form with autonomic instability — is life-threatening and is the principal indication for urgent ECT.

Ask OpenScientist

Ask a research question about Catatonia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

9
Pathophys.
16
Phenotypes
4
Hypotheses
5
Gaps
19
Pathograph
1
Genes
5
Medical Actions
10
Differentials
🏷

Classifications

Harrison's Part
NEUROLOGIC
◈

Mechanistic Hypotheses

4
Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
distributed_psychomotor_network_model CANONICAL
Evidence balance 2 support
The best-supported current model treats catatonia as a final common phenotype of disturbed psychomotor regulation. Heterogeneous upstream liabilities converge on a shared set of networks — cortico-striatal-thalamic, cortico-cerebellar, orbitofrontal, cingulate, and motor-premotor — destabilizing them and producing a recognizable but internally heterogeneous syndrome. The model's explanatory strength is that it accommodates the syndrome's transdiagnostic breadth, which any schizophrenia-centered or single-transmitter account fails to do. Its principal weakness is sampling: the imaging literature is dominated by schizophrenia-spectrum cohorts and by post-acute rather than acute states.
Pathograph links
Heterogeneous Upstream Liability -> Distributed Psychomotor Network Destabilization INDIRECT KNOWN INTERMEDIATES The summary edge of the canonical model: heterogeneous liabilities reach the shared networks through the neurochemical nodes curated above.
Cortical GABA-A Receptor-Mediated Inhibition Deficit -> Distributed Psychomotor Network Destabilization DIRECT Loss of cortical inhibitory tone destabilizes the motor and emotional-motor networks that generate the syndrome.
Reduced Striatal Dopaminergic Transmission -> Distributed Psychomotor Network Destabilization DIRECT Striatal dopaminergic hypofunction is transmitted to cortex through the cortico-striatal-thalamic loop, which is one of the destabilized networks.
Glutamatergic NMDA Receptor Perturbation and Neuroinflammation -> Distributed Psychomotor Network Destabilization DIRECT Glutamatergic perturbation destabilizes the same shared psychomotor networks reached by the GABAergic and dopaminergic routes.
Orbitofrontal Emotional-Motor Processing Dysfunction -> Distributed Psychomotor Network Destabilization DIRECT Orbitofrontal dysfunction is one of the named components of the distributed network model.
Distributed Psychomotor Network Destabilization -> Hypokinetic Psychomotor Output DIRECT Network destabilization biased toward reduced movement initiation produces stupor, mutism, catalepsy, and posturing.
Distributed Psychomotor Network Destabilization -> Hyperkinetic and Aberrant-Volitional Output DIRECT The same destabilization can produce excitement, stereotypy, and echophenomena, which is why the two outputs are siblings rather than alternatives.
Distributed Psychomotor Network Destabilization -> Autonomic Decompensation INDIRECT UNKNOWN INTERMEDIATES A minority of episodes progress to autonomic instability; the intermediates linking network destabilization to autonomic failure are not established.
Show evidence (2 references)
PMID:42431537 SUPPORT Human Clinical
"The best-supported mechanistic model to date comes from neuroimaging studies implicating cortico-striatal-thalamic, cortico-cerebellar, orbitofrontal, cingulate, and motor-premotor networks."
States the network membership of the canonical model and its evidential basis in neuroimaging.
PMID:42431537 SUPPORT Human Clinical
"the evidence supports a convergent model in which diverse upstream liabilities destabilize shared psychomotor networks, producing a recognizable but heterogeneous syndrome"
The convergence claim that justifies modeling catatonia as one entity with many entry points rather than as many disease-specific mechanisms.
Cortical GABA-A receptor deficit as the proximate substrate of the akinetic form
gabaergic_deficit_model ALTERNATIVE
Evidence balance 2 support
The oldest mechanistically specific account starts from the syndrome's most striking pharmacological fact — akinesia and anxiety that remit within minutes of lorazepam — and locates the lesion at the GABA-A receptor. In vivo benzodiazepine-receptor SPECT in akinetic catatonia found reduced iomazenil binding in the left sensorimotor cortex, interpreted as decreased GABA-A receptor density, with symptom severity correlating with the binding deficit. This is recorded as ALTERNATIVE rather than CANONICAL because it is a single small study of the akinetic subtype, and because the broader neurochemical evidence points to interacting rather than single-transmitter disturbance.
Pathograph links
Heterogeneous Upstream Liability -> Cortical GABA-A Receptor-Mediated Inhibition Deficit INDIRECT UNKNOWN INTERMEDIATES How a given upstream liability arrives at a cortical GABA-A receptor deficit is not established; the link is recorded with its intermediates unknown rather than asserted as direct.
Cortical GABA-A Receptor-Mediated Inhibition Deficit -> Distributed Psychomotor Network Destabilization DIRECT Loss of cortical inhibitory tone destabilizes the motor and emotional-motor networks that generate the syndrome.
Show evidence (2 references)
PMID:10486389 SUPPORT Human Clinical
"Reduced iomazenil binding suggests decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia."
Direct in vivo receptor-imaging evidence for the GABA-A deficit this hypothesis is built on.
PMID:42431537 SUPPORT Human Clinical
"Neurochemical evidence supports the notion of interacting disturbances in GABAergic inhibition, glutamatergic/NMDA-mediated excitation, and dopaminergic modulation rather than a single-transmitter explanation."
Qualifies the GABA-only account: the contemporary synthesis treats GABAergic inhibition as one interacting term, not the whole mechanism.
Reduced striatal dopaminergic transmission as a transdiagnostic psychomotor substrate
striatal_dopamine_hypofunction_model ALTERNATIVE
Evidence balance 2 support
A parallel account places the proximate lesion in the dorsal striatum, proposing that reduced dopaminergic transmission is a transdiagnostic substrate for psychomotor retardation shared by Parkinson disease, drug-induced parkinsonism, neuroleptic malignant syndrome, catatonia, and depression. Two clinical observations anchor it: dopamine antagonists can induce catatonia, and dopaminergic medication can relieve it. It is recorded as ALTERNATIVE because the primary evidence is a hypothesis-level synthesis about psychomotor retardation broadly rather than catatonia specifically, and because CSF dopamine-catabolite measurement has been inconsistent and nonspecific.
Pathograph links
Heterogeneous Upstream Liability -> Reduced Striatal Dopaminergic Transmission INDIRECT UNKNOWN INTERMEDIATES Dopamine-antagonist exposure and withdrawal states are the clearest route; for psychiatric and medical liabilities the intermediates are not established.
Reduced Striatal Dopaminergic Transmission -> Distributed Psychomotor Network Destabilization DIRECT Striatal dopaminergic hypofunction is transmitted to cortex through the cortico-striatal-thalamic loop, which is one of the destabilized networks.
Show evidence (2 references)
PMID:40966690 SUPPORT Human Clinical
"we discuss the hypothesis that reduced striatal dopaminergic transmission is a transdiagnostic substrate for psychomotor retardation underlying the motor features of conditions such as Parkinson's disease, drug-induced parkinsonism, neuroleptic malignant syndrome, catatonia and depression"
States the hypothesis and explicitly includes catatonia among the conditions it is proposed to cover. Marked PARTIAL because the authors present it as a hypothesis under review, not an established finding.
PMID:40966690 SUPPORT Human Clinical
"Parkinson's disease and catatonia generally respond well to dopaminergic medication. In contrast, dopamine antagonists can induce both parkinsonism and catatonia."
The bidirectional pharmacological argument — dopamine blockade induces, dopaminergic treatment relieves — that motivates the striatal dopamine arm.
Immune-mediated NMDA receptor perturbation in autoimmune subgroups
immune_mediated_model EMERGING
Evidence balance 2 support
In a mechanistically distinct subgroup, catatonia arises from autoimmune perturbation of glutamatergic signaling — most clearly in NMDA receptor antibody encephalitis, where catatonia is present in a majority of reported cases. The subgroup matters clinically because its treatment is immunotherapy directed at the antibody-mediated process, not only benzodiazepines. The arm is EMERGING rather than established as a general mechanism because it accounts for a subgroup rather than the syndrome, and because peripheral inflammatory biomarkers remain nonspecific.
Pathograph links
Heterogeneous Upstream Liability -> Glutamatergic NMDA Receptor Perturbation and Neuroinflammation DIRECT In the autoimmune subgroup the upstream condition acts directly, through receptor-directed antibodies and CNS inflammation.
Glutamatergic NMDA Receptor Perturbation and Neuroinflammation -> Distributed Psychomotor Network Destabilization DIRECT Glutamatergic perturbation destabilizes the same shared psychomotor networks reached by the GABAergic and dopaminergic routes.
Show evidence (2 references)
PMID:42431537 SUPPORT Human Clinical
"Immune mechanisms are particularly relevant in subgroups, especially in autoimmune encephalitis and inflammatory CNS conditions, whereas peripheral biomarkers remain nonspecific."
Scopes the immune arm to subgroups and records the biomarker limitation that keeps it from generalizing.
PMID:32070914 SUPPORT Human Clinical
"Catatonia was present in 60% of these cases."
Quantifies how strongly catatonia tracks with NMDA receptor antibody encephalitis in the published case literature.
?

Discussions and Knowledge Gaps

5
Is there a single mechanism or biomarker that accounts for catatonia across its psychiatric, neurologic, autoimmune, and medical contexts, or is the convergent-network account the correct final level of explanation?
KNOWLEDGE GAP OPEN catatonia_no_unified_mechanism
Attached to
pathophysiology#Distributed Psychomotor Network Destabilization
This is the central open question of the entry and the reason the pathophysiology is curated as several parallel routes into one hub rather than as a single chain. The literature is explicit that no single biomarker or unified mechanism fully accounts for catatonia across contexts, and that the neurochemical evidence describes interacting rather than single-transmitter disturbance. Resolving it matters practically: if the convergent-network account is correct, subtype-sensitive treatment selection is the achievable goal and a universal catatonia biomarker is not.
Proposed experiments
Prospective acute-state multimodal phenotyping across upstream causes
exp_catatonia_acute_state_multimodal_cohort
Recruit an acute-state catatonia cohort stratified by upstream cause (mood disorder, schizophrenia-spectrum, autoimmune encephalitis, medical or drug-induced) and acquire the same multimodal battery in every stratum: resting-state and emotional-task fMRI, GABA-A receptor imaging, striatal dopaminergic imaging, CSF and serum neuronal autoantibodies, and dimensional Bush-Francis and Northoff scale scoring. The discriminating test is whether the network signature is shared across strata while the neurochemical signature differs by stratum — the prediction of the convergent model — or whether each stratum has its own network signature.
Show evidence (2 references)
PMID:42431537 SUPPORT Human Clinical
"No single biomarker or unified mechanism fully accounts for catatonia across contexts."
The explicit statement of the gap this discussion records.
PMID:42431537 SUPPORT Human Clinical
"Future progress will depend on dimensional phenotyping, multimodal biomarker integration, and subtype-sensitive treatment research."
The authors' own statement of what would close the gap, which the proposed experiment operationalizes.
How much of the imaging evidence for the distributed-network model is an artifact of studying schizophrenia-spectrum patients in the post-acute state rather than catatonia in the acute state across its full diagnostic range?
KNOWLEDGE GAP OPEN catatonia_sampling_and_acute_state_bias
Attached to
pathophysiology#Distributed Psychomotor Network Destabilization pathophysiology#Orbitofrontal Emotional-Motor Processing Dysfunction
The two limitations compound. The multimodal MRI evidence comes from a schizophrenia-spectrum sample, and the orbitofrontal fMRI evidence comes from post-acute patients whose authors explicitly interpret the finding as a trait marker of predisposition rather than a state correlate. A network signature derived under both constraints may describe the vulnerability of one diagnostic group rather than the mechanism of the acute syndrome. This is a limit on how causally the hub node may be read, and it is recorded rather than smoothed over.
Show evidence (2 references)
PMID:42431537 SUPPORT Human Clinical
"key limitations remain, including the overrepresentation of schizophrenia-spectrum samples and limited acute-state data"
Names both sampling limitations directly.
PMID:15279056 SUPPORT Human Clinical
"Because we investigated postacute patients, orbitofrontal cortical alterations may be interpreted as a trait marker predisposing for development of catatonic syndrome"
A worked instance of the acute-state limitation, stated by the original authors.
Can treatment recommendations for catatonia be raised above their current evidence ceiling, given that first-line therapy rests on observational studies and case series rather than randomized trials?
KNOWLEDGE GAP OPEN catatonia_evidence_quality_ceiling
Attached to
pathophysiology#Distributed Psychomotor Network Destabilization
Catatonia is unusual in that its first-line treatments are both effective and poorly evidenced by contemporary standards. The BAP consensus guideline states plainly that clinical trials were uncommon and that its recommendations are mainly informed by small observational studies, case series, and case reports. The 76% lorazepam response rate curated in this entry comes from an open, non-randomized prospective protocol in 28 patients. Any downstream use of this entry for therapeutic inference should carry that ceiling with it.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"Clinical trials were uncommon, and the recommendations in this guideline are mainly informed by small observational studies, case series and case reports, which highlights the need for randomised controlled trials and prospective cohort studies in this area."
The guideline's own statement of the evidence ceiling.
Are malignant catatonia and neuroleptic malignant syndrome one entity with two names, or two entities that share a striatal dopaminergic substrate?
CONTROVERSY OPEN catatonia_malignant_vs_nms
Attached to
pathophysiology#Autonomic Decompensation pathophysiology#Reduced Striatal Dopaminergic Transmission
The two syndromes share precipitants, an overlapping motor phenotype, autonomic instability, and a treatment pathway that converges on withdrawing the offending agent and ECT. The striatal-dopamine hypothesis supplies a mechanism that would unify them. Against unification, malignant catatonia occurs without dopamine-antagonist exposure. The question is recorded as an open controversy because the entity distinction currently rests on exposure history rather than on any mechanistic discriminator.
Show evidence (2 references)
PMID:40966690 SUPPORT Human Clinical
"In addition, there are close epidemiological relationships between depression and Parkinson's disease, and between catatonia and neuroleptic malignant syndrome."
Records the epidemiological relationship that a shared-substrate account would explain.
PMID:35861966 SUPPORT Human Clinical
"Malignant catatonia describes catatonia that presents with clinically significant autonomic abnormalities including change in temperature, blood pressure, heart rate, and respiratory rate."
Supplies the definition of the entity on the catatonia side of the controversy.
HPO has no term for catatonia, or for stupor, catalepsy, or waxy flexibility. Should a new-term request be filed, and until then how should the syndrome be bound in entries where it appears as a phenotype?
CURATION TODO OPEN catatonia_hpo_term_gap
Attached to
pathophysiology#Hypokinetic Psychomotor Output
Searched HPO for catatonia, stupor, catalepsy, and waxy flexibility on 2026-08-14: none exists. HPO does carry the component signs used in this entry (Mutism HP:0002300, Abnormal posturing HP:0002533, Negativism HP:0410291, Motor stereotypy HP:0000733, Echolalia HP:0010529, Facial grimacing HP:0000273, Akinesia HP:0002304, Rigidity HP:0002063). MONDO does have catatonia (MONDO:0800105), which is why this is curated as a disease entry rather than as a disease-like phenotype module — the module family for disease-like phenotypes requires both an HP and a MONDO identifier. The practical consequence is that a disorder in which catatonia occurs cannot bind it as a single phenotype term and must either enumerate the component signs or leave the phenotype unbound, as the Schizophrenia entry currently does. An HPO new-term request would close this.
Upstream ontology gap, not a dismech bug. Recorded here so the decision is auditable rather than rediscovered.
⚙

Pathophysiology

9
Heterogeneous Upstream Liability
The entry point to catatonia is not a single lesion but any of a wide range of upstream conditions: mood disorders, schizophrenia-spectrum illness, autism, autoimmune encephalitis (particularly NMDA receptor encephalitis), systemic lupus erythematosus, thyroid disease, epilepsy, and medication-induced or withdrawal states. This node exists so that the downstream mechanism can be curated once and referenced from the many disorders in which catatonia appears, rather than duplicated per disease. Genetic and developmental data are consistent with this framing: they support vulnerability rather than a single syndrome-specific architecture.
Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder Cortical GABA-A receptor deficit as the proximate substrate of the akinetic form Immune-mediated NMDA receptor perturbation in autoimmune subgroups Reduced striatal dopaminergic transmission as a transdiagnostic psychomotor substrate
Downstream
Cortical GABA-A Receptor-Mediated Inhibition Deficit How a given upstream liability arrives at a cortical GABA-A receptor deficit is not established; the link is recorded with its intermediates unknown rather than asserted as direct. Cortical GABA-A receptor deficit as the proximate substrate of the akinetic form
Reduced Striatal Dopaminergic Transmission Dopamine-antagonist exposure and withdrawal states are the clearest route; for psychiatric and medical liabilities the intermediates are not established. Reduced striatal dopaminergic transmission as a transdiagnostic psychomotor substrate
Glutamatergic NMDA Receptor Perturbation and Neuroinflammation In the autoimmune subgroup the upstream condition acts directly, through receptor-directed antibodies and CNS inflammation. Immune-mediated NMDA receptor perturbation in autoimmune subgroups
Distributed Psychomotor Network Destabilization The summary edge of the canonical model: heterogeneous liabilities reach the shared networks through the neurochemical nodes curated above. Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Show evidence (3 references)
PMID:42431537 SUPPORT Human Clinical
"Catatonia is a transdiagnostic psychomotor syndrome that occurs across psychiatric, neurologic, neurodevelopmental, autoimmune, and general medical conditions."
Establishes the breadth of upstream conditions this node stands for.
PMID:37236789 SUPPORT Human Clinical
"It can occur in a wide range of psychiatric and neurological conditions, including depression, mania, schizophrenia, autism, autoimmune encephalitis (particularly NMDAR encephalitis), systemic lupus erythematosus, thyroid disease, epilepsy and medication-induced and -withdrawal states."
Enumerates the specific upstream conditions, which is what makes this node a genuine convergence point rather than a placeholder.
PMID:42431537 SUPPORT Human Clinical
"Genetic and developmental data support vulnerability rather than unitarity, implicating synaptic, GABAergic, and microglial processes without a single syndrome-specific architecture."
Supports treating the upstream layer as liability rather than as a unitary cause.
Cortical GABA-A Receptor-Mediated Inhibition Deficit
Reduced GABA-A receptor-mediated inhibition in sensorimotor and adjacent cortex is the proximate molecular substrate most directly evidenced in akinetic catatonia. In vivo SPECT with iodine-123-iomazenil, a benzodiazepine-site ligand, showed significantly lower binding in the left sensorimotor cortex in catatonic patients than in psychiatric controls matched for age, sex, medication, and underlying diagnosis — so the finding is not attributable to the underlying psychiatric illness or its treatment. Catatonic motor and affective symptom severity correlated with the binding deficit. Regional cerebral blood flow was separately reduced in right lower prefrontal and parietal cortex, implicating a second, perfusion-level site. This node is the molecular target of benzodiazepine treatment.
Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder Cortical GABA-A receptor deficit as the proximate substrate of the akinetic form
GABAergic neuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology.
gamma-aminobutyric acid signaling pathway GO:0007214 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased gamma-aminobutyric acid signaling pathway (GO:0007214). GO:0007214 is a biological process from the Gene Ontology. ↓ DECREASED GABAergic synaptic transmission GO:0051932 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased GABAergic synaptic transmission, annotated with synaptic transmission, GABAergic (GO:0051932). GO:0051932 is a biological process from the Gene Ontology. ↓ DECREASED
primary motor cortex UBERON:0001384 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in primary motor cortex (UBERON:0001384). UBERON:0001384 is an anatomical location from the Uberon multi-species anatomy ontology. parietal lobe UBERON:0001872 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in parietal lobe (UBERON:0001872). UBERON:0001872 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Distributed Psychomotor Network Destabilization Loss of cortical inhibitory tone destabilizes the motor and emotional-motor networks that generate the syndrome. Cortical GABA-A receptor deficit as the proximate substrate of the akinetic form Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Show evidence (3 references)
PMID:10486389 SUPPORT Human Clinical
"Catatonic patients showed significantly lower iomazenil binding and altered right-left relations in the left sensorimotor cortex compared with psychiatric (p<0.001) and healthy (p<0.001) controls."
The primary measurement, and the psychiatric-control comparison is what makes it specific to catatonia rather than to the underlying illness.
PMID:10486389 SUPPORT Human Clinical
"Catatonia is a psychomotor syndrome with concomittant akinesia and anxiety which both respond almost immediately to benzodiazepines such as lorazepam."
The pharmacological observation that motivates placing a GABA-A lesion at this point in the graph.
PMID:10486389 SUPPORT Human Clinical
"In addition, there was significantly lower r-CBF in the right lower prefrontal and parietal cortex in catatonia"
Records the second, perfusion-level site — the reason this node points onward to the distributed network rather than standing alone.
Reduced Striatal Dopaminergic Transmission
Reduced dopaminergic transmission in the dorsal striatum shifts the balance of basal-ganglia direct and indirect pathway output toward inhibition of movement initiation and speed. The clinical signature is bidirectional: dopamine antagonists can induce catatonia and parkinsonism, and dopaminergic medication can relieve catatonia. This node is also the proposed point of contact between catatonia and neuroleptic malignant syndrome, which share precipitants and an overlapping motor phenotype.
Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder Reduced striatal dopaminergic transmission as a transdiagnostic psychomotor substrate
dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology. medium spiny neuron CL:1001474 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves medium spiny neuron (CL:1001474). CL:1001474 is a cell type from the Cell Ontology.
dopamine receptor signaling pathway GO:0007212 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased dopamine receptor signaling pathway, annotated with G protein-coupled dopamine receptor signaling pathway (GO:0007212). GO:0007212 is a biological process from the Gene Ontology. ↓ DECREASED
striatum UBERON:0002435 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in striatum (UBERON:0002435). UBERON:0002435 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Distributed Psychomotor Network Destabilization Striatal dopaminergic hypofunction is transmitted to cortex through the cortico-striatal-thalamic loop, which is one of the destabilized networks. Reduced striatal dopaminergic transmission as a transdiagnostic psychomotor substrate Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Show evidence (3 references)
PMID:40966690 SUPPORT Human Clinical
"Neuroimaging studies also generally support the association of psychomotor retardation with reduced dopaminergic transmission, particularly in the dorsal striatum."
Localizes the reduction to the dorsal striatum. PARTIAL because the imaging evidence cited is for psychomotor retardation across disorders rather than for catatonia alone.
PMID:40966690 SUPPORT Human Clinical
"Parkinson's disease and catatonia generally respond well to dopaminergic medication. In contrast, dopamine antagonists can induce both parkinsonism and catatonia."
The induction-and-relief pattern that supports a causal role for striatal dopamine in the catatonic motor phenotype.
PMID:35861966 SUPPORT Human Clinical
"Many of the established predisposing and precipitating factors for catatonia such as exposure to neuroleptic medications or withdrawal states are common in the setting of critical illness."
Independent clinical corroboration that dopamine-blocking exposure and withdrawal are established precipitants.
Glutamatergic NMDA Receptor Perturbation and Neuroinflammation
In the autoimmune subgroup, antibodies against the NMDA receptor perturb glutamatergic excitation and are accompanied by CNS inflammation. Catatonia is present in a majority of published NMDA receptor antibody encephalitis cases, and its phenomenology in that setting is weighted toward the hypokinetic pole — immobility/stupor and mutism predominate — while excitement co-occurs in a third of patients, illustrating within-episode heterogeneity. Microglial processes are among those implicated by genetic and developmental data, though peripheral inflammatory biomarkers remain nonspecific.
Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder Immune-mediated NMDA receptor perturbation in autoimmune subgroups
glutamatergic neuron CL:0000679 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glutamatergic neuron (CL:0000679). CL:0000679 is a cell type from the Cell Ontology. microglial cell CL:0000129 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves microglial cell (CL:0000129). CL:0000129 is a cell type from the Cell Ontology.
glutamate receptor signaling pathway GO:0007215 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased glutamate receptor signaling pathway (GO:0007215). GO:0007215 is a biological process from the Gene Ontology. ↓ DECREASED microglial cell activation GO:0001774 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased microglial cell activation (GO:0001774). GO:0001774 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Distributed Psychomotor Network Destabilization Glutamatergic perturbation destabilizes the same shared psychomotor networks reached by the GABAergic and dopaminergic routes. Immune-mediated NMDA receptor perturbation in autoimmune subgroups Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Show evidence (3 references)
PMID:32070914 SUPPORT Human Clinical
"The most prevalent signs were immobility/stupor (70%), mutism (67%), excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and rigidity (30%)."
Characterizes the catatonic phenotype produced by this specific autoimmune route.
PMID:32070914 SUPPORT Human Clinical
"Immobility/stupor and excitement co-occurred in the same patient in 33% of cases."
Direct evidence that hypokinetic and hyperkinetic components coexist within one episode, which is why they are curated as parallel outputs of one network node rather than as separate diseases.
PMID:42431537 SUPPORT Human Clinical
"Immune mechanisms are particularly relevant in subgroups, especially in autoimmune encephalitis and inflammatory CNS conditions, whereas peripheral biomarkers remain nonspecific."
Scopes this node to subgroups and records why it cannot be generalized to all catatonia.
Orbitofrontal Emotional-Motor Processing Dysfunction
Catatonia couples emotional and motor abnormality, and functional imaging during emotional stimulation localizes that coupling to the orbitofrontal cortex and its connectivity with premotor cortex. Catatonic behavioral and affective symptoms correlate with orbitofrontal activity while motor symptoms track medial prefrontal activity, which is the imaging counterpart of the clinical observation that the syndrome is not purely motor. Because the patients studied were post-acute, the orbitofrontal alteration was interpreted as a trait marker of predisposition rather than a state correlate of the acute episode — an important limitation on how causally this node may be read.
Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
modulation of chemical synaptic transmission GO:0050804 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal modulation of chemical synaptic transmission (GO:0050804). GO:0050804 is a biological process from the Gene Ontology. ⚠ ABNORMAL
orbitofrontal cortex UBERON:0004167 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in orbitofrontal cortex (UBERON:0004167). UBERON:0004167 is an anatomical location from the Uberon multi-species anatomy ontology. prefrontal cortex UBERON:0000451 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in prefrontal cortex (UBERON:0000451). UBERON:0000451 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Distributed Psychomotor Network Destabilization Orbitofrontal dysfunction is one of the named components of the distributed network model. Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Show evidence (3 references)
PMID:15279056 SUPPORT Human Clinical
"Catatonic patients showed alterations in the orbitofrontal cortical activation pattern and in functional connectivity to the premotor cortex in negative and positive emotions compared to psychiatric and healthy controls."
The primary finding locating the emotional-motor coupling defect at the orbitofrontal-premotor link.
PMID:15279056 SUPPORT Human Clinical
"Catatonic behavioral and affective symptoms correlated significantly with orbitofrontal activity, whereas catatonic motor symptoms were rather related to medial prefrontal activity."
Dissociates the affective and motor components onto different prefrontal subregions.
PMID:15279056 SUPPORT Human Clinical
"Because we investigated postacute patients, orbitofrontal cortical alterations may be interpreted as a trait marker predisposing for development of catatonic syndrome"
The authors' own caveat: post-acute sampling means this may index predisposition rather than the acute mechanism.
Distributed Psychomotor Network Destabilization
The convergence hub of the entry. Multimodal MRI in schizophrenia-spectrum patients with versus without catatonia found predominantly frontothalamic and corticostriatal abnormalities in the catatonic group, with behavioral-symptom scores mapping onto a joint structural-functional system spanning cerebellar and prefrontal/cortical motor regions. Combined with the orbitofrontal and cingulate findings, this defines the shared network substrate that diverse upstream liabilities destabilize. Every downstream clinical manifestation in this entry is generated from this node rather than from any one neurochemical route.
Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
modulation of chemical synaptic transmission GO:0050804 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated modulation of chemical synaptic transmission (GO:0050804). GO:0050804 is a biological process from the Gene Ontology. ↕ DYSREGULATED
prefrontal cortex UBERON:0000451 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in prefrontal cortex (UBERON:0000451). UBERON:0000451 is an anatomical location from the Uberon multi-species anatomy ontology. striatum UBERON:0002435 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in striatum (UBERON:0002435). UBERON:0002435 is an anatomical location from the Uberon multi-species anatomy ontology. thalamus UBERON:0001897 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in thalamus, annotated with dorsal plus ventral thalamus (UBERON:0001897). UBERON:0001897 is an anatomical location from the Uberon multi-species anatomy ontology. cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebellum (UBERON:0002037). UBERON:0002037 is an anatomical location from the Uberon multi-species anatomy ontology. primary motor cortex UBERON:0001384 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in primary motor cortex (UBERON:0001384). UBERON:0001384 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Hypokinetic Psychomotor Output Network destabilization biased toward reduced movement initiation produces stupor, mutism, catalepsy, and posturing. Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Hyperkinetic and Aberrant-Volitional Output The same destabilization can produce excitement, stereotypy, and echophenomena, which is why the two outputs are siblings rather than alternatives. Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Autonomic Decompensation A minority of episodes progress to autonomic instability; the intermediates linking network destabilization to autonomic failure are not established. Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
Show evidence (3 references)
PMID:31174212 SUPPORT Human Clinical
"we found predominantly frontothalamic and corticostriatal abnormalities in SSD patients with catatonia"
Identifies the network abnormality specific to catatonia within a schizophrenia-spectrum sample, controlling for the underlying diagnosis.
PMID:31174212 SUPPORT Human Clinical
"NCRS behavioral scores were associated with a joint structural and functional system that predominantly included cerebellar and prefrontal/cortical motor regions."
Adds the cerebellar and cortical motor components of the network and ties them to symptom severity.
PMID:42431537 SUPPORT Human Clinical
"The best-supported mechanistic model to date comes from neuroimaging studies implicating cortico-striatal-thalamic, cortico-cerebellar, orbitofrontal, cingulate, and motor-premotor networks."
Establishes this set of networks as the best-supported mechanistic account, which is why it is modeled as the hub.
Hypokinetic Psychomotor Output
The hypokinetic pole of the syndrome — immobility and stupor, mutism, catalepsy and posturing, rigidity, negativism. This is the classical presentation and the one in which the GABA-A receptor and striatal dopamine findings were made. It is a pole rather than a subtype: hyperkinetic features frequently co-occur within the same episode.
locomotory behavior GO:0007626 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased locomotory behavior (GO:0007626). GO:0007626 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Pneumonia Prolonged immobility and stupor impair airway clearance and mobility, producing infective complications including pneumonia.
Deep venous thrombosis Sustained immobility is the classical risk factor for venous stasis and deep venous thrombosis.
Pulmonary embolism Immobility-associated deep venous thrombosis embolises to the pulmonary arteries.
Rhabdomyolysis Sustained posturing, rigidity, and immobility drive skeletal muscle breakdown.
Disseminated intravascular coagulation Reported as a systemic complication of catatonic stupor in the same cohort.
Show evidence (2 references)
PMID:32070914 SUPPORT Human Clinical
"The phenomenological profile of catatonia in this sample of cases of NMDAr-AbE was characterised by a preponderance of signs in the hypokinetic spectrum."
Names the hypokinetic spectrum as a distinguishable output and shows it predominating in a defined subgroup.
PMID:35861966 SUPPORT Human Clinical
"The clinical picture of catatonia ranges from akinetic stupor to severe motoric excitement."
Places akinetic stupor at one end of the clinical range this node represents.
Hyperkinetic and Aberrant-Volitional Output
The hyperkinetic and aberrant-volitional pole — excitement, agitation not prompted by external stimuli, stereotypy, mannerism, echolalia and echopraxia. Dimensional work identifies these as components that overlap with the hypokinetic pole within a single episode, so an entry that modeled catatonia as either akinetic or excited would misrepresent the syndrome.
locomotory behavior GO:0007626 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased locomotory behavior (GO:0007626). GO:0007626 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:42431537 SUPPORT Human Clinical
"catatonia is internally heterogeneous, with hypokinetic, hyperkinetic, and aberrant-volitional components that often overlap within the same episode"
The dimensional claim that justifies curating hyperkinetic and aberrant-volitional features as a distinct but co-occurring output.
PMID:32070914 SUPPORT Human Clinical
"However, excitement often co-occurred in these patients suggesting that fluctuations in catatonic semiology may be frequent."
Empirical support for within-episode fluctuation between the two poles.
Autonomic Decompensation
Malignant catatonia is catatonia with clinically significant autonomic abnormality — disturbance of temperature, blood pressure, heart rate, and respiratory rate. It is a life-threatening form of acute brain dysfunction and is the principal reason catatonia is a medical emergency rather than only a psychiatric one; untreated, it may be fatal. Its phenotypic overlap with neuroleptic malignant syndrome is longstanding and unresolved.
Show evidence (2 references)
PMID:35861966 SUPPORT Human Clinical
"Malignant catatonia describes catatonia that presents with clinically significant autonomic abnormalities including change in temperature, blood pressure, heart rate, and respiratory rate."
Defines the autonomic decompensation this node represents.
PMID:35861966 SUPPORT Human Clinical
"Prompt recognition and treatment of catatonia are crucial because malignant catatonia may be fatal without treatment."
Records the outcome that makes this node the highest-stakes branch of the graph.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Catatonia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

16
Blood 2
Deep venous thrombosis HP:0002625 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Deep venous thrombosis (HP:0002625). HP:0002625 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"increased risk of various infections (pneumonia, urinary tract infection and sepsis), disseminated intravascular coagulation, rhabdomyolysis, dehydration, deep vein thrombosis, pulmonary embolus, urinary retention, decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia and..."
Lists deep vein thrombosis among the complications of catatonic stupor.
Disseminated intravascular coagulation HP:0005521 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Disseminated intravascular coagulation (HP:0005521). HP:0005521 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"increased risk of various infections (pneumonia, urinary tract infection and sepsis), disseminated intravascular coagulation, rhabdomyolysis, dehydration, deep vein thrombosis, pulmonary embolus, urinary retention, decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia and..."
Lists disseminated intravascular coagulation among the complications of catatonic stupor.
Cardiovascular 2
Tachycardia HP:0001649 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tachycardia (HP:0001649). HP:0001649 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35861966 SUPPORT Human Clinical
"Malignant catatonia describes catatonia that presents with clinically significant autonomic abnormalities including change in temperature, blood pressure, heart rate, and respiratory rate."
Names heart-rate change among the defining autonomic abnormalities of malignant catatonia.
Pulmonary embolism HP:0002204 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary embolism (HP:0002204). HP:0002204 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"increased risk of various infections (pneumonia, urinary tract infection and sepsis), disseminated intravascular coagulation, rhabdomyolysis, dehydration, deep vein thrombosis, pulmonary embolus, urinary retention, decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia and..."
Lists pulmonary embolus among the complications of catatonic stupor.
Immune 1
Pneumonia HP:0002090 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pneumonia (HP:0002090). HP:0002090 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"increased risk of various infections (pneumonia, urinary tract infection and sepsis), disseminated intravascular coagulation, rhabdomyolysis, dehydration, deep vein thrombosis, pulmonary embolus, urinary retention, decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia and..."
Names pneumonia among the complications carried by catatonic stupor in the cited cohort.
Metabolism 1
Fever HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35861966 SUPPORT Human Clinical
"Malignant catatonia describes catatonia that presents with clinically significant autonomic abnormalities including change in temperature, blood pressure, heart rate, and respiratory rate."
Names temperature change among the defining autonomic abnormalities of malignant catatonia.
Musculoskeletal 2
Rigidity HP:0002063 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Rigidity (HP:0002063). HP:0002063 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32070914 SUPPORT Human Clinical
"The most prevalent signs were immobility/stupor (70%), mutism (67%), excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and rigidity (30%)."
Reports rigidity among the ascertained catatonic signs.
Rhabdomyolysis HP:0003201 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Rhabdomyolysis (HP:0003201). HP:0003201 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"increased risk of various infections (pneumonia, urinary tract infection and sepsis), disseminated intravascular coagulation, rhabdomyolysis, dehydration, deep vein thrombosis, pulmonary embolus, urinary retention, decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia and..."
Lists rhabdomyolysis among the complications of catatonic stupor.
Nervous System 1
Agitation HP:0000713 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Agitation (HP:0000713). HP:0000713 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35861966 SUPPORT Human Clinical
"The clinical picture of catatonia ranges from akinetic stupor to severe motoric excitement."
Establishes severe motoric excitement as a recognized pole of the syndrome.
Other 7
Mutism HP:0002300 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mutism (HP:0002300). HP:0002300 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32070914 SUPPORT Human Clinical
"The most prevalent signs were immobility/stupor (70%), mutism (67%), excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and rigidity (30%)."
Quantifies mutism among the most prevalent catatonic signs in a defined cohort.
Akinesia HP:0002304 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Akinesia (HP:0002304). HP:0002304 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35861966 SUPPORT Human Clinical
"The clinical picture of catatonia ranges from akinetic stupor to severe motoric excitement."
Establishes akinetic stupor as a recognized presentation of catatonia.
Abnormal posturing HP:0002533 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal posturing (HP:0002533). HP:0002533 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32070914 SUPPORT Human Clinical
"The most prevalent signs were immobility/stupor (70%), mutism (67%), excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and rigidity (30%)."
Reports posturing/catalepsy as an ascertained catatonic sign with its frequency in the cohort.
Motor stereotypy HP:0000733 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor stereotypy (HP:0000733). HP:0000733 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32070914 SUPPORT Human Clinical
"The most prevalent signs were immobility/stupor (70%), mutism (67%), excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and rigidity (30%)."
Reports stereotypies among the ascertained catatonic signs.
Negativism HP:0410291 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Negativism (HP:0410291). HP:0410291 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37236789 SUPPORT Human Clinical
"Negativism (resistance to instructions, which might even entail doing the opposite to them)"
The DSM-5-TR criterion definition, from the BAP concise guideline's summary of diagnostic criteria.
Echolalia HP:0010529 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Echolalia (HP:0010529). HP:0010529 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37236789 SUPPORT Human Clinical
"Echolalia (repetition of another person's speech)"
The DSM-5-TR criterion definition for echolalia as a catatonic sign.
Facial grimacing HP:0000273 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Facial grimacing (HP:0000273). HP:0000273 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12384773 SUPPORT Human Clinical
"The disorder is characterized by qualitative hyperkinetic and akinetic psychomotor disturbances through acute psychotic episodes and debilitating symptoms in the long term, with psychomotor weakness, grimacing facial movements and apathy."
Reports grimacing facial movements as a persistent feature in the periodic-catatonia phenotype.
🧬

Genetic Associations

1
Chromosome 15q15 periodic catatonia susceptibility locus (Periodic catatonia, a familial sub-phenotype with recurrent hyperkinetic and akinetic psychomotor episodes, maps to a major susceptibility locus on chromosome 15q15, confirmed in a second independent genome scan. No causal gene has been established at the locus, and the same study demonstrated genetic heterogeneity between families, so this is recorded as a susceptibility locus rather than as a catatonia gene.)
relationship_type: SUSCEPTIBILITY
Show evidence (2 references)
PMID:12384773 SUPPORT Human Clinical
"Here, we confirm mapping of a major gene locus on chromosome 15q15 in a second genome scan in a new set of four multiplex families."
Independent confirmation of the linkage signal in a new family set.
PMID:12384773 SUPPORT Human Clinical
"Analysis of individual families showed that one large family showed linkage, whereas two others could be clearly excluded, confirming genetic heterogeneity."
The heterogeneity caveat: the locus explains some families and is excluded in others, so it cannot be read as a general catatonia gene.
💊

Medical Actions

5
Lorazepam
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: lorazepam CHEBI:6539 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses lorazepam (CHEBI:6539). CHEBI:6539 is a therapeutic agent from Chemical Entities of Biological Interest.
A benzodiazepine positive allosteric modulator at the GABA-A receptor and the first-line treatment for catatonia, sometimes required in very high doses. In the defining prospective study, catatonic signs resolved in 16 of 21 patients (76%) who completed a lorazepam trial. The near-immediate response of akinesia and anxiety to lorazepam is also the clinical observation that motivated the GABA-A receptor hypothesis.
Mechanism Target:
RESTORES Cortical GABA-A Receptor-Mediated Inhibition Deficit — Positive allosteric modulation at the benzodiazepine site increases GABA-A receptor-mediated chloride conductance, restoring the inhibitory tone that is deficient at this node. The same receptor population imaged by iomazenil SPECT is the drug's binding site, which is what makes this a mechanistically specific rather than symptomatic treatment.
Show evidence (1 reference)
PMID:10486389 SUPPORT Human Clinical
"Catatonia is a psychomotor syndrome with concomittant akinesia and anxiety which both respond almost immediately to benzodiazepines such as lorazepam."
Links the drug's effect directly to the receptor population this node describes.
Show evidence (2 references)
PMID:8686484 SUPPORT Human Clinical
"In 16 of 21 patients (76%) who received a complete trial of lorazepam (11 with initial intravenous challenge), catatonic signs resolved."
The prospective, quantitatively monitored response rate underpinning first-line status.
PMID:37236789 SUPPORT Human Clinical
"First-line treatment comprises benzodiazepines and/or electroconvulsive therapy. The benzodiazepine of choice is lorazepam, which is sometimes used in very high doses."
Current guideline statement of first-line status and the drug of choice.
Electroconvulsive therapy
Action: electroconvulsive therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is electroconvulsive therapy (NCIT:C93303). NCIT:C93303 is a clinical intervention from the NCI Thesaurus. Ontology label: Electroconvulsive Therapy NCIT:C93303
ECT is first-line alongside benzodiazepines and is the treatment of choice for catatonia refractory to benzodiazepines and for malignant catatonia, where delay is life-threatening. In the defining prospective study, all four patients who failed lorazepam responded promptly to ECT. Its mechanism is not receptor-specific; it is curated here as modulating the distributed network node rather than any single neurochemical route.
Mechanism Target:
MODULATES Distributed Psychomotor Network Destabilization — ECT acts on the destabilized network as a whole rather than on a defined molecular target, which is consistent with its efficacy in cases that do not respond to GABA-A-directed treatment.
Show evidence (1 reference)
PMID:8686484 SUPPORT Human Clinical
"Four patients failing lorazepam responded promptly to ECT."
Efficacy in benzodiazepine non-responders is the clinical evidence that ECT acts beyond the GABA-A node.
Show evidence (2 references)
PMID:8686484 SUPPORT Human Clinical
"It is concluded that lorazepam and ECT are effective treatments for catatonia."
The study's own summary conclusion on efficacy.
PMID:35861966 SUPPORT Human Clinical
"Catatonia typically improves with benzodiazepines and treatment of its underlying psychiatric or medical conditions, with electroconvulsive therapy reserved for catatonia refractory to benzodiazepines or for malignant catatonia."
Defines the two indications that position ECT relative to benzodiazepines.
Treatment of the underlying condition
Action: Therapeutic ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Therapeutic Procedure (NCIT:C49236). NCIT:C49236 is a clinical intervention from the NCI Thesaurus. NCIT:C49236
Because catatonia is a convergence syndrome, treating the upstream liability is part of definitive management rather than an adjunct — most consequentially, immunotherapy in autoimmune encephalitis and withdrawal of a precipitating dopamine antagonist. Multidisciplinary working between psychiatrists and physicians is frequently required.
Mechanism Target:
INHIBITS Heterogeneous Upstream Liability — Removing or treating the upstream liability addresses the entry point to the mechanism rather than its downstream expression.
Show evidence (1 reference)
PMID:35861966 SUPPORT Human Clinical
"Catatonia typically improves with benzodiazepines and treatment of its underlying psychiatric or medical conditions"
States that treatment of the underlying condition is part of what resolves catatonia.
Show evidence (1 reference)
PMID:37236789 SUPPORT Human Clinical
"Multidisciplinary working between psychiatrists and physicians is often essential."
Guideline statement reflecting that the upstream cause is frequently medical rather than psychiatric.
Amantadine and memantine
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: amantadine CHEBI:2618 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses amantadine (CHEBI:2618). CHEBI:2618 is a therapeutic agent from Chemical Entities of Biological Interest. memantine CHEBI:64312 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses memantine (CHEBI:64312). CHEBI:64312 is a therapeutic agent from Chemical Entities of Biological Interest.
Uncompetitive NMDA receptor antagonists used as second-line pharmacotherapy when benzodiazepines fail or are not tolerated. Amantadine additionally enhances central dopamine release and delays synaptic dopamine reuptake, which is the proposed reason it suits a syndrome hypothesised to involve hypodopaminergic tone. The supporting literature is case reports and case series rather than trials, so this is curated as a mechanistically motivated second-line option, not an established one.
Mechanism Target:
MODULATES Glutamatergic NMDA Receptor Perturbation and Neuroinflammation — Uncompetitive NMDA receptor antagonism is proposed to rebalance, rather than simply suppress, the NMDA receptor perturbation this node describes — acting on prefrontal GABA-A parvalbumin interneurons and on striatal NMDA signalling within the cortico-striato-thalamo-cortical circuitry.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"The NMDA receptor antagonists, amantadine and memantine, may reset the problems related to reduced dopamine and GABA in the CSTC circuitries"
States the proposed mechanism by which these agents act on the NMDA receptor perturbation curated at this node.
Show evidence (2 references)
PMID:37039129 SUPPORT Human Clinical
"Medications such as amantadine and memantine serve as uncompetitive antagonists of the NMDA receptor and thus may be helpful in patients with catatonia."
Guideline statement placing both agents in the catatonia treatment repertoire, with the hedged wording preserved.
PMID:37039129 SUPPORT Human Clinical
"Amantadine as monotherapy often abolished catatonia after a few doses."
Reports the observed response, but the underlying evidence is a systematic review of 11 articles describing 18 cases, so it supports a signal rather than an established effect size — hence PARTIAL.
Avoidance of antipsychotic medication
Action: avoidance of contraindicated medicationsNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is avoidance of contraindicated medications, annotated with Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Antipsychotic exposure can both induce and worsen catatonia, and catatonia is itself a risk factor for neuroleptic malignant syndrome, so antipsychotic use in an actively catatonic patient is a recognised hazard. The guideline describes this as one of the most controversial areas of catatonia management rather than an absolute prohibition — antipsychotics may still be indicated for an underlying psychotic illness once catatonia has resolved.
Mechanism Target:
INHIBITS Reduced Striatal Dopaminergic Transmission — Withholding dopamine antagonists removes an avoidable driver of the striatal dopaminergic hypofunction curated at this node — the same exposure that defines antipsychotic-induced catatonia and that anchors the malignant-catatonia versus neuroleptic malignant syndrome differential.
Show evidence (1 reference)
PMID:37039129 SUPPORT Human Clinical
"Antipsychotic medications can induce catatonia"
States that the drug class can cause the mechanism this node describes, which is what makes withholding it mechanistically directed rather than merely cautious.
Show evidence (2 references)
PMID:37039129 SUPPORT Human Clinical
"in some studies of catatonia, the use of antipsychotics has been associated with poor outcomes"
Outcome evidence behind the avoidance recommendation, quoted with the guideline's own hedge ("in some studies").
PMID:37039129 SUPPORT Human Clinical
"The use of antipsychotics is one of the most controversial areas in catatonia management"
Records that the guideline frames this as contested rather than settled, which is why the entry curates avoidance without asserting an absolute contraindication.
🔬

Diagnosis

2
Bush-Francis Catatonia Rating Scale
The most widely used instrument for ascertaining and quantifying catatonia. Its screening component defines the core signs, and the full scale is sensitive to change, making it the standard outcome measure for treatment response.
Show evidence (2 references)
PMID:8686484 SUPPORT Human Clinical
"The rating scale has predictive value and displays sensitivity to change in clinical status."
Establishes the scale's utility as a quantitative response measure, not only a diagnostic checklist.
PMID:32070914 SUPPORT Human Clinical
"Cases were searched for clinical data in keeping with core catatonic signs by applying the screening instrument of the Bush-Francis Catatonia Rating Scale."
Demonstrates the screening instrument being used as the ascertainment standard in systematic research.
Lorazepam challenge test
A parenteral lorazepam challenge is used both diagnostically and prognostically: a positive response to the initial challenge predicted the eventual response to a full lorazepam trial. This is a rare instance of a psychiatric test whose predictive validity rests on the same mechanism as the treatment.
Show evidence (1 reference)
PMID:8686484 SUPPORT Human Clinical
"A positive response to an initial parenteral challenge predicted final lorazepam response, as did length of catatonic symptoms prior to treatment."
The prospective evidence that the challenge test predicts treatment response.
📊

Prevalence

4
Clinical samples worldwide (psychiatric and medical settings)
Point Prevalence 9000.0 per 100,000 (6900.0–11700.0) >1 in 1,000
Pooled mean of 9.0% across 74 studies (k = 80, n = 110,764), 95% CI 6.9-11.7%. Heterogeneity was very high (I2 = 98%) with evidence of publication bias, so the point estimate should be read as an order of magnitude rather than a precise rate.
Show evidence (1 reference)
PMID:29140521 SUPPORT Human Clinical
"mean catatonia prevalence was 9.0% (k = 80, n = 110764; 95% CI = 6.9-11.7, I2 = 98%, publication bias P < .01)"
The pooled meta-analytic estimate, quoted with its confidence interval and heterogeneity statistic.
Worldwide, general population
Annual Incidence 10.0 per 100,000 1–9 per 100,000
Incidence of approximately 10 per 100,000 person-years, as cited in the BAP concise guideline.
Show evidence (1 reference)
PMID:37236789 SUPPORT Human Clinical
"It has an incidence of ≈10 per 100,000 person-years."
States the incidence figure itself, which is what rate_per_100000 records. The source's approximation sign is reproduced verbatim inside the quote so that the numeral is carried by the snippet rather than supplied from outside it.
Individuals with autism spectrum disorder
Point Prevalence 10400.0 per 100,000 (5800.0–18000.0) >1 in 1,000
Meta-analysis of seven studies comprising 969 individuals with ASD.
Show evidence (1 reference)
PMID:34906264 SUPPORT Human Clinical
"Our meta-analysis showed that 10.4% (5.8-18.0 95%CI) of individuals with ASD have catatonia."
The pooled prevalence of catatonia within the ASD population.
Published NMDA receptor antibody encephalitis case reports
Point Prevalence 60000.0 per 100,000 >1 in 1,000
60% of 189 subjects across 139 case reports met a two-core-sign threshold applied retrospectively using the Bush-Francis screening instrument. Case reports are a selected literature, so this is an upper-bound estimate for the autoimmune subgroup, not a population rate.
Show evidence (1 reference)
PMID:32070914 SUPPORT Human Clinical
"Catatonia was present in 60% of these cases."
The proportion of NMDA receptor antibody encephalitis cases meeting catatonia criteria in this systematic review.
🔀

Differential Diagnoses

10

Conditions with similar clinical presentations that must be differentiated from Catatonia:

Neuroleptic malignant syndrome
Overlapping Features Malignant catatonia and neuroleptic malignant syndrome share precipitants (dopamine antagonist exposure), an overlapping motor phenotype, and autonomic instability. Whether they are one entity or two has been debated for decades and is not settled here.
Distinguishing Features
  • NMS is defined by a temporal relationship to dopamine-antagonist exposure, whereas malignant catatonia may arise without it.
  • In practice the distinction is often retrospective, and treatment converges on withdrawal of the offending agent, supportive care, and ECT.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including malignant catatonia/neuroleptic malignant syndrome.
Delirium
Overlapping Features Delirium and catatonia can co-occur, and catatonia comorbid with delirium may respond less well to standard treatment.
Distinguishing Features
  • Delirium is defined by fluctuating attention and awareness; catatonia by the psychomotor sign cluster.
  • Their coexistence is a recognized clinical problem rather than a diagnostic error.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including delirium.
Akinetic mutism and abulia
Overlapping Features Both present with reduced speech and movement without the fuller catatonic sign cluster.
Distinguishing Features
  • Catalepsy, waxy flexibility, negativism, and echophenomena favor catatonia.
  • A response to a parenteral lorazepam challenge favors catatonia.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including abulia/akinetic mutism.
Late-stage Parkinson disease
Overlapping Features Shares hypokinesia, rigidity, and reduced verbal output with the akinetic presentation of catatonia; the shared striatal dopaminergic substrate is the basis of the proposal that catatonia be considered a psychiatric parkinsonism.
Distinguishing Features
  • Parkinson disease shows a progressive course with rest tremor and levodopa responsiveness.
  • Catatonia is typically episodic and benzodiazepine-responsive.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including late-stage Parkinson's disease.
Locked-in syndrome
Overlapping Features Preserved awareness with near-total loss of voluntary movement can be mistaken for stupor.
Distinguishing Features
  • Locked-in syndrome follows a structural brainstem lesion demonstrable on imaging.
  • Vertical eye movement and blinking are spared in locked-in syndrome.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including locked-in syndrome.
Serotonin syndrome
Overlapping Features Autonomic instability with altered mental status and neuromuscular abnormality overlaps with malignant catatonia.
Distinguishing Features
  • Serotonin syndrome follows serotonergic drug exposure.
  • Clonus and hyperreflexia are characteristic, rather than catalepsy and negativism.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including serotonin syndrome.
Stiff-person syndrome
Overlapping Features Autoimmune rigidity with axial and limb muscle stiffness can be mistaken for catatonic rigidity and posturing, and both may respond partially to benzodiazepines — which removes the lorazepam challenge as a discriminator.
Distinguishing Features
  • Stiff-person syndrome is associated with anti-GAD65 (or anti-amphiphysin) antibodies and continuous motor unit activity on EMG.
  • Stiffness is stimulus-sensitive and painful, without the echophenomena, negativism, or mutism of the catatonic sign cluster.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including stiff-person syndrome.
Akathisia
Overlapping Features Antipsychotic-associated motor restlessness overlaps with the hyperkinetic and agitated pole of catatonia, and the two share an antipsychotic-exposure history.
Distinguishing Features
  • Akathisia is dominated by a subjective sense of inner restlessness that the patient can usually report.
  • Movement in akathisia is purposeful relief-seeking, rather than the non-goal-directed stereotypy and mannerism of catatonia.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including akathisia.
Major neurocognitive disorders
Overlapping Features Advanced dementia can present with reduced speech, reduced spontaneous movement, and apparent negativism. Catatonia may also occur on top of a major neurocognitive disorder rather than instead of it.
Distinguishing Features
  • Major neurocognitive disorders follow a chronic progressive course, whereas catatonia is typically episodic with a definable onset.
  • Catalepsy, waxy flexibility, and echophenomena are not features of dementia itself.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including major neurocognitive disorders.
Mania
Overlapping Features Manic excitement overlaps with the hyperkinetic pole of catatonia, and excited catatonia has historically been conflated with mania.
Distinguishing Features
  • Manic agitation is goal-directed and accompanied by elevated mood, pressured speech, and reduced need for sleep.
  • Catatonic excitement is non-goal-directed and co-occurs with hypokinetic signs within the same episode.
Show evidence (1 reference)
PMID:40368005 SUPPORT Human Clinical
"abulia/akinetic mutism, delirium, major neurocognitive disorders, locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome, akathisia, mania, malignant catatonia/neuroleptic malignant syndrome, autoimmune encephalitis, and serotonin syndrome"
The APA Resource Document enumerates the catatonia differential, including mania.
{ }

Source YAML

click to show 
name: Catatonia
creation_date: '2026-08-14T09:00:00Z'
category: Psychiatric
synonyms:
- catatonic syndrome
- catatonic state
- catatonic disorder
description: >-
  Catatonia is a transdiagnostic psychomotor syndrome that arises across
  psychiatric, neurologic, neurodevelopmental, autoimmune, and general medical
  conditions rather than belonging to any one of them. It is defined
  clinically by a cluster of motor, volitional, affective, and behavioral signs
  — stupor, mutism, catalepsy and posturing, negativism, stereotypy, echolalia,
  grimacing, and agitation — and it is internally heterogeneous, with
  hypokinetic, hyperkinetic, and aberrant-volitional components that may
  overlap within a single episode.

  The mechanism is best described as convergence rather than as a single causal
  chain. Diverse upstream liabilities — a psychiatric illness, autoimmune
  encephalitis, a metabolic derangement, or exposure to and withdrawal from
  dopamine-blocking drugs — destabilize a shared set of psychomotor networks
  (cortico-striatal-thalamic, cortico-cerebellar, orbitofrontal, cingulate, and
  motor-premotor). Neurochemically, the best-evidenced disturbances are a
  cortical GABA-A receptor deficit (the direct correlate of the syndrome's
  near-immediate response to lorazepam), reduced striatal dopaminergic
  transmission, and glutamatergic/NMDA-mediated dysfunction, with immune
  mechanisms specifically relevant in autoimmune subgroups. Importantly, no
  single biomarker or unified mechanism accounts for catatonia across all
  contexts, and this entry models that heterogeneity explicitly as competing
  and complementary hypotheses rather than collapsing it into one chain.

  Treatment is unusually mechanism-legible for a psychiatric syndrome:
  benzodiazepines (lorazepam) and electroconvulsive therapy are both
  first-line and both act on the nodes curated here. Malignant catatonia — the
  form with autonomic instability — is life-threatening and is the principal
  indication for urgent ECT.
disease_term:
  preferred_term: catatonia
  term:
    id: MONDO:0800105
    label: catatonia
parents:
- Mental Health Disorder
- Psychomotor Disorder
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
mechanistic_hypotheses:
- hypothesis_group_id: distributed_psychomotor_network_model
  hypothesis_label: Catatonia as distributed psychomotor network dysfunction, not a single-lesion disorder
  status: CANONICAL
  description: >-
    The best-supported current model treats catatonia as a final common
    phenotype of disturbed psychomotor regulation. Heterogeneous upstream
    liabilities converge on a shared set of networks — cortico-striatal-thalamic,
    cortico-cerebellar, orbitofrontal, cingulate, and motor-premotor —
    destabilizing them and producing a recognizable but internally
    heterogeneous syndrome. The model's explanatory strength is that it
    accommodates the syndrome's transdiagnostic breadth, which any
    schizophrenia-centered or single-transmitter account fails to do. Its
    principal weakness is sampling: the imaging literature is dominated by
    schizophrenia-spectrum cohorts and by post-acute rather than acute states.
  evidence:
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The best-supported mechanistic model to date comes from neuroimaging
      studies implicating cortico-striatal-thalamic, cortico-cerebellar,
      orbitofrontal, cingulate, and motor-premotor networks.
    explanation: >-
      States the network membership of the canonical model and its evidential
      basis in neuroimaging.
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the evidence supports a convergent model in which diverse upstream
      liabilities destabilize shared psychomotor networks, producing a
      recognizable but heterogeneous syndrome
    explanation: >-
      The convergence claim that justifies modeling catatonia as one entity
      with many entry points rather than as many disease-specific mechanisms.
- hypothesis_group_id: gabaergic_deficit_model
  hypothesis_label: Cortical GABA-A receptor deficit as the proximate substrate of the akinetic form
  status: ALTERNATIVE
  description: >-
    The oldest mechanistically specific account starts from the syndrome's most
    striking pharmacological fact — akinesia and anxiety that remit within
    minutes of lorazepam — and locates the lesion at the GABA-A receptor.
    In vivo benzodiazepine-receptor SPECT in akinetic catatonia found reduced
    iomazenil binding in the left sensorimotor cortex, interpreted as decreased
    GABA-A receptor density, with symptom severity correlating with the binding
    deficit. This is recorded as ALTERNATIVE rather than CANONICAL because it
    is a single small study of the akinetic subtype, and because the broader
    neurochemical evidence points to interacting rather than single-transmitter
    disturbance.
  evidence:
  - reference: PMID:10486389
    reference_title: "Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reduced iomazenil binding suggests decreased density of GABA-A receptors
      in the left sensorimotor cortex in akinetic catatonia.
    explanation: >-
      Direct in vivo receptor-imaging evidence for the GABA-A deficit this
      hypothesis is built on.
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurochemical evidence supports the notion of interacting disturbances in
      GABAergic inhibition, glutamatergic/NMDA-mediated excitation, and
      dopaminergic modulation rather than a single-transmitter explanation.
    explanation: >-
      Qualifies the GABA-only account: the contemporary synthesis treats
      GABAergic inhibition as one interacting term, not the whole mechanism.
- hypothesis_group_id: striatal_dopamine_hypofunction_model
  hypothesis_label: Reduced striatal dopaminergic transmission as a transdiagnostic psychomotor substrate
  status: ALTERNATIVE
  description: >-
    A parallel account places the proximate lesion in the dorsal striatum,
    proposing that reduced dopaminergic transmission is a transdiagnostic
    substrate for psychomotor retardation shared by Parkinson disease,
    drug-induced parkinsonism, neuroleptic malignant syndrome, catatonia, and
    depression. Two clinical observations anchor it: dopamine antagonists can
    induce catatonia, and dopaminergic medication can relieve it. It is
    recorded as ALTERNATIVE because the primary evidence is a hypothesis-level
    synthesis about psychomotor retardation broadly rather than catatonia
    specifically, and because CSF dopamine-catabolite measurement has been
    inconsistent and nonspecific.
  evidence:
  - reference: PMID:40966690
    reference_title: Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we discuss the hypothesis that reduced striatal dopaminergic transmission
      is a transdiagnostic substrate for psychomotor retardation underlying the
      motor features of conditions such as Parkinson's disease, drug-induced
      parkinsonism, neuroleptic malignant syndrome, catatonia and depression
    explanation: >-
      States the hypothesis and explicitly includes catatonia among the
      conditions it is proposed to cover. Marked PARTIAL because the authors
      present it as a hypothesis under review, not an established finding.
  - reference: PMID:40966690
    reference_title: Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Parkinson's disease and catatonia generally respond well to dopaminergic
      medication. In contrast, dopamine antagonists can induce both parkinsonism
      and catatonia.
    explanation: >-
      The bidirectional pharmacological argument — dopamine blockade induces,
      dopaminergic treatment relieves — that motivates the striatal dopamine
      arm.
- hypothesis_group_id: immune_mediated_model
  hypothesis_label: Immune-mediated NMDA receptor perturbation in autoimmune subgroups
  status: EMERGING
  description: >-
    In a mechanistically distinct subgroup, catatonia arises from autoimmune
    perturbation of glutamatergic signaling — most clearly in NMDA receptor
    antibody encephalitis, where catatonia is present in a majority of reported
    cases. The subgroup matters clinically because its treatment is
    immunotherapy directed at the antibody-mediated process, not only
    benzodiazepines. The arm is EMERGING rather than established as a general
    mechanism because it accounts for a subgroup rather than the syndrome, and
    because peripheral inflammatory biomarkers remain nonspecific.
  evidence:
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immune mechanisms are particularly relevant in subgroups, especially in
      autoimmune encephalitis and inflammatory CNS conditions, whereas
      peripheral biomarkers remain nonspecific.
    explanation: >-
      Scopes the immune arm to subgroups and records the biomarker limitation
      that keeps it from generalizing.
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Catatonia was present in 60% of these cases.
    explanation: >-
      Quantifies how strongly catatonia tracks with NMDA receptor antibody
      encephalitis in the published case literature.
pathophysiology:
- name: Heterogeneous Upstream Liability
  biological_scale: ORGANISM
  description: >-
    The entry point to catatonia is not a single lesion but any of a wide range
    of upstream conditions: mood disorders, schizophrenia-spectrum illness,
    autism, autoimmune encephalitis (particularly NMDA receptor encephalitis),
    systemic lupus erythematosus, thyroid disease, epilepsy, and
    medication-induced or withdrawal states. This node exists so that the
    downstream mechanism can be curated once and referenced from the many
    disorders in which catatonia appears, rather than duplicated per disease.
    Genetic and developmental data are consistent with this framing: they
    support vulnerability rather than a single syndrome-specific architecture.
  evidence:
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Catatonia is a transdiagnostic psychomotor syndrome that occurs across
      psychiatric, neurologic, neurodevelopmental, autoimmune, and general
      medical conditions.
    explanation: >-
      Establishes the breadth of upstream conditions this node stands for.
  - reference: PMID:37236789
    reference_title: The diagnosis and treatment of catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It can occur in a wide range of psychiatric and neurological conditions,
      including depression, mania, schizophrenia, autism, autoimmune
      encephalitis (particularly NMDAR encephalitis), systemic lupus
      erythematosus, thyroid disease, epilepsy and medication-induced and
      -withdrawal states.
    explanation: >-
      Enumerates the specific upstream conditions, which is what makes this
      node a genuine convergence point rather than a placeholder.
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic and developmental data support vulnerability rather than
      unitarity, implicating synaptic, GABAergic, and microglial processes
      without a single syndrome-specific architecture.
    explanation: >-
      Supports treating the upstream layer as liability rather than as a
      unitary cause.
  downstream:
  - target: Cortical GABA-A Receptor-Mediated Inhibition Deficit
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - gabaergic_deficit_model
    description: >-
      How a given upstream liability arrives at a cortical GABA-A receptor
      deficit is not established; the link is recorded with its intermediates
      unknown rather than asserted as direct.
  - target: Reduced Striatal Dopaminergic Transmission
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - striatal_dopamine_hypofunction_model
    description: >-
      Dopamine-antagonist exposure and withdrawal states are the clearest
      route; for psychiatric and medical liabilities the intermediates are not
      established.
  - target: Glutamatergic NMDA Receptor Perturbation and Neuroinflammation
    causal_link_type: DIRECT
    hypothesis_groups:
    - immune_mediated_model
    description: >-
      In the autoimmune subgroup the upstream condition acts directly, through
      receptor-directed antibodies and CNS inflammation.
  - target: Distributed Psychomotor Network Destabilization
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - distributed_psychomotor_network_model
    description: >-
      The summary edge of the canonical model: heterogeneous liabilities reach
      the shared networks through the neurochemical nodes curated above.
- name: Cortical GABA-A Receptor-Mediated Inhibition Deficit
  biological_scale: MOLECULAR
  description: >-
    Reduced GABA-A receptor-mediated inhibition in sensorimotor and adjacent
    cortex is the proximate molecular substrate most directly evidenced in
    akinetic catatonia. In vivo SPECT with iodine-123-iomazenil, a
    benzodiazepine-site ligand, showed significantly lower binding in the left
    sensorimotor cortex in catatonic patients than in psychiatric controls
    matched for age, sex, medication, and underlying diagnosis — so the finding
    is not attributable to the underlying psychiatric illness or its treatment.
    Catatonic motor and affective symptom severity correlated with the binding
    deficit. Regional cerebral blood flow was separately reduced in right lower
    prefrontal and parietal cortex, implicating a second, perfusion-level site.
    This node is the molecular target of benzodiazepine treatment.
  locations:
  - preferred_term: primary motor cortex
    term:
      id: UBERON:0001384
      label: primary motor cortex
  - preferred_term: parietal lobe
    term:
      id: UBERON:0001872
      label: parietal lobe
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  - preferred_term: GABAergic synaptic transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: DECREASED
  evidence:
  - reference: PMID:10486389
    reference_title: "Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Catatonic patients showed significantly lower iomazenil binding and
      altered right-left relations in the left sensorimotor cortex compared with
      psychiatric (p<0.001) and healthy (p<0.001) controls.
    explanation: >-
      The primary measurement, and the psychiatric-control comparison is what
      makes it specific to catatonia rather than to the underlying illness.
  - reference: PMID:10486389
    reference_title: "Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Catatonia is a psychomotor syndrome with concomittant akinesia and anxiety
      which both respond almost immediately to benzodiazepines such as lorazepam.
    explanation: >-
      The pharmacological observation that motivates placing a GABA-A lesion at
      this point in the graph.
  - reference: PMID:10486389
    reference_title: "Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, there was significantly lower r-CBF in the right lower
      prefrontal and parietal cortex in catatonia
    explanation: >-
      Records the second, perfusion-level site — the reason this node points
      onward to the distributed network rather than standing alone.
  downstream:
  - target: Distributed Psychomotor Network Destabilization
    causal_link_type: DIRECT
    hypothesis_groups:
    - gabaergic_deficit_model
    - distributed_psychomotor_network_model
    description: >-
      Loss of cortical inhibitory tone destabilizes the motor and
      emotional-motor networks that generate the syndrome.
- name: Reduced Striatal Dopaminergic Transmission
  biological_scale: CELLULAR
  description: >-
    Reduced dopaminergic transmission in the dorsal striatum shifts the balance
    of basal-ganglia direct and indirect pathway output toward inhibition of
    movement initiation and speed. The clinical signature is bidirectional:
    dopamine antagonists can induce catatonia and parkinsonism, and
    dopaminergic medication can relieve catatonia. This node is also the
    proposed point of contact between catatonia and neuroleptic malignant
    syndrome, which share precipitants and an overlapping motor phenotype.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: dopamine receptor signaling pathway
    term:
      id: GO:0007212
      label: G protein-coupled dopamine receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:40966690
    reference_title: Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuroimaging studies also generally support the association of psychomotor
      retardation with reduced dopaminergic transmission, particularly in the
      dorsal striatum.
    explanation: >-
      Localizes the reduction to the dorsal striatum. PARTIAL because the
      imaging evidence cited is for psychomotor retardation across disorders
      rather than for catatonia alone.
  - reference: PMID:40966690
    reference_title: Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Parkinson's disease and catatonia generally respond well to dopaminergic
      medication. In contrast, dopamine antagonists can induce both parkinsonism
      and catatonia.
    explanation: >-
      The induction-and-relief pattern that supports a causal role for striatal
      dopamine in the catatonic motor phenotype.
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Many of the established predisposing and precipitating factors for
      catatonia such as exposure to neuroleptic medications or withdrawal states
      are common in the setting of critical illness.
    explanation: >-
      Independent clinical corroboration that dopamine-blocking exposure and
      withdrawal are established precipitants.
  downstream:
  - target: Distributed Psychomotor Network Destabilization
    causal_link_type: DIRECT
    hypothesis_groups:
    - striatal_dopamine_hypofunction_model
    - distributed_psychomotor_network_model
    description: >-
      Striatal dopaminergic hypofunction is transmitted to cortex through the
      cortico-striatal-thalamic loop, which is one of the destabilized networks.
- name: Glutamatergic NMDA Receptor Perturbation and Neuroinflammation
  biological_scale: CELLULAR
  description: >-
    In the autoimmune subgroup, antibodies against the NMDA receptor perturb
    glutamatergic excitation and are accompanied by CNS inflammation. Catatonia
    is present in a majority of published NMDA receptor antibody encephalitis
    cases, and its phenomenology in that setting is weighted toward the
    hypokinetic pole — immobility/stupor and mutism predominate — while
    excitement co-occurs in a third of patients, illustrating within-episode
    heterogeneity. Microglial processes are among those implicated by genetic
    and developmental data, though peripheral inflammatory biomarkers remain
    nonspecific.
  cell_types:
  - preferred_term: glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: glutamate receptor signaling pathway
    term:
      id: GO:0007215
      label: glutamate receptor signaling pathway
    modifier: DECREASED
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
    modifier: INCREASED
  evidence:
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent signs were immobility/stupor (70%), mutism (67%),
      excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and
      rigidity (30%).
    explanation: >-
      Characterizes the catatonic phenotype produced by this specific
      autoimmune route.
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immobility/stupor and excitement co-occurred in the same patient in 33% of
      cases.
    explanation: >-
      Direct evidence that hypokinetic and hyperkinetic components coexist
      within one episode, which is why they are curated as parallel outputs of
      one network node rather than as separate diseases.
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immune mechanisms are particularly relevant in subgroups, especially in
      autoimmune encephalitis and inflammatory CNS conditions, whereas
      peripheral biomarkers remain nonspecific.
    explanation: >-
      Scopes this node to subgroups and records why it cannot be generalized to
      all catatonia.
  downstream:
  - target: Distributed Psychomotor Network Destabilization
    causal_link_type: DIRECT
    hypothesis_groups:
    - immune_mediated_model
    - distributed_psychomotor_network_model
    description: >-
      Glutamatergic perturbation destabilizes the same shared psychomotor
      networks reached by the GABAergic and dopaminergic routes.
- name: Orbitofrontal Emotional-Motor Processing Dysfunction
  biological_scale: TISSUE
  description: >-
    Catatonia couples emotional and motor abnormality, and functional imaging
    during emotional stimulation localizes that coupling to the orbitofrontal
    cortex and its connectivity with premotor cortex. Catatonic behavioral and
    affective symptoms correlate with orbitofrontal activity while motor
    symptoms track medial prefrontal activity, which is the imaging counterpart
    of the clinical observation that the syndrome is not purely motor. Because
    the patients studied were post-acute, the orbitofrontal alteration was
    interpreted as a trait marker of predisposition rather than a state
    correlate of the acute episode — an important limitation on how causally
    this node may be read.
  locations:
  - preferred_term: orbitofrontal cortex
    term:
      id: UBERON:0004167
      label: orbitofrontal cortex
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  biological_processes:
  - preferred_term: modulation of chemical synaptic transmission
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
    modifier: ABNORMAL
  evidence:
  - reference: PMID:15279056
    reference_title: "Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Catatonic patients showed alterations in the orbitofrontal cortical
      activation pattern and in functional connectivity to the premotor cortex
      in negative and positive emotions compared to psychiatric and healthy
      controls.
    explanation: >-
      The primary finding locating the emotional-motor coupling defect at the
      orbitofrontal-premotor link.
  - reference: PMID:15279056
    reference_title: "Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Catatonic behavioral and affective symptoms correlated significantly with
      orbitofrontal activity, whereas catatonic motor symptoms were rather
      related to medial prefrontal activity.
    explanation: >-
      Dissociates the affective and motor components onto different prefrontal
      subregions.
  - reference: PMID:15279056
    reference_title: "Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Because we investigated postacute patients, orbitofrontal cortical
      alterations may be interpreted as a trait marker predisposing for
      development of catatonic syndrome
    explanation: >-
      The authors' own caveat: post-acute sampling means this may index
      predisposition rather than the acute mechanism.
  downstream:
  - target: Distributed Psychomotor Network Destabilization
    causal_link_type: DIRECT
    hypothesis_groups:
    - distributed_psychomotor_network_model
    description: >-
      Orbitofrontal dysfunction is one of the named components of the
      distributed network model.
- name: Distributed Psychomotor Network Destabilization
  biological_scale: TISSUE
  description: >-
    The convergence hub of the entry. Multimodal MRI in schizophrenia-spectrum
    patients with versus without catatonia found predominantly frontothalamic
    and corticostriatal abnormalities in the catatonic group, with
    behavioral-symptom scores mapping onto a joint structural-functional system
    spanning cerebellar and prefrontal/cortical motor regions. Combined with
    the orbitofrontal and cingulate findings, this defines the shared network
    substrate that diverse upstream liabilities destabilize. Every downstream
    clinical manifestation in this entry is generated from this node rather
    than from any one neurochemical route.
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: thalamus
    term:
      id: UBERON:0001897
      label: dorsal plus ventral thalamus
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: primary motor cortex
    term:
      id: UBERON:0001384
      label: primary motor cortex
  biological_processes:
  - preferred_term: modulation of chemical synaptic transmission
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:31174212
    reference_title: Multimodal Magnetic Resonance Imaging Data Fusion Reveals Distinct Patterns of Abnormal Brain Structure and Function in Catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we found predominantly frontothalamic and corticostriatal abnormalities in
      SSD patients with catatonia
    explanation: >-
      Identifies the network abnormality specific to catatonia within a
      schizophrenia-spectrum sample, controlling for the underlying diagnosis.
  - reference: PMID:31174212
    reference_title: Multimodal Magnetic Resonance Imaging Data Fusion Reveals Distinct Patterns of Abnormal Brain Structure and Function in Catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NCRS behavioral scores were associated with a joint structural and
      functional system that predominantly included cerebellar and
      prefrontal/cortical motor regions.
    explanation: >-
      Adds the cerebellar and cortical motor components of the network and ties
      them to symptom severity.
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The best-supported mechanistic model to date comes from neuroimaging
      studies implicating cortico-striatal-thalamic, cortico-cerebellar,
      orbitofrontal, cingulate, and motor-premotor networks.
    explanation: >-
      Establishes this set of networks as the best-supported mechanistic
      account, which is why it is modeled as the hub.
  downstream:
  - target: Hypokinetic Psychomotor Output
    causal_link_type: DIRECT
    hypothesis_groups:
    - distributed_psychomotor_network_model
    description: >-
      Network destabilization biased toward reduced movement initiation
      produces stupor, mutism, catalepsy, and posturing.
  - target: Hyperkinetic and Aberrant-Volitional Output
    causal_link_type: DIRECT
    hypothesis_groups:
    - distributed_psychomotor_network_model
    description: >-
      The same destabilization can produce excitement, stereotypy, and
      echophenomena, which is why the two outputs are siblings rather than
      alternatives.
  - target: Autonomic Decompensation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - distributed_psychomotor_network_model
    description: >-
      A minority of episodes progress to autonomic instability; the
      intermediates linking network destabilization to autonomic failure are
      not established.
- name: Hypokinetic Psychomotor Output
  biological_scale: ORGANISM
  description: >-
    The hypokinetic pole of the syndrome — immobility and stupor, mutism,
    catalepsy and posturing, rigidity, negativism. This is the classical
    presentation and the one in which the GABA-A receptor and striatal dopamine
    findings were made. It is a pole rather than a subtype: hyperkinetic
    features frequently co-occur within the same episode.
  biological_processes:
  - preferred_term: locomotory behavior
    term:
      id: GO:0007626
      label: locomotory behavior
    modifier: DECREASED
  evidence:
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The phenomenological profile of catatonia in this sample of cases of
      NMDAr-AbE was characterised by a preponderance of signs in the hypokinetic
      spectrum.
    explanation: >-
      Names the hypokinetic spectrum as a distinguishable output and shows it
      predominating in a defined subgroup.
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical picture of catatonia ranges from akinetic stupor to severe
      motoric excitement.
    explanation: >-
      Places akinetic stupor at one end of the clinical range this node
      represents.
  downstream:
  - target: Pneumonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Prolonged immobility and stupor impair airway clearance and mobility,
      producing infective complications including pneumonia.
    evidence:
    - reference: PMID:37039129
      reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        increased risk of various infections (pneumonia, urinary tract infection
        and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
        dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
        decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
        and liver dysfunction
      explanation: >-
        Cohort evidence that catatonic stupor carries an increased risk of this
        complication.
  - target: Deep venous thrombosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Sustained immobility is the classical risk factor for venous stasis and
      deep venous thrombosis.
    evidence:
    - reference: PMID:37039129
      reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        increased risk of various infections (pneumonia, urinary tract infection
        and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
        dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
        decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
        and liver dysfunction
      explanation: >-
        Cohort evidence that catatonic stupor carries an increased risk of this
        complication.
  - target: Pulmonary embolism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Immobility-associated deep venous thrombosis embolises to the pulmonary
      arteries.
    evidence:
    - reference: PMID:37039129
      reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        increased risk of various infections (pneumonia, urinary tract infection
        and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
        dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
        decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
        and liver dysfunction
      explanation: >-
        Cohort evidence that catatonic stupor carries an increased risk of this
        complication.
  - target: Rhabdomyolysis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Sustained posturing, rigidity, and immobility drive skeletal muscle
      breakdown.
    evidence:
    - reference: PMID:37039129
      reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        increased risk of various infections (pneumonia, urinary tract infection
        and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
        dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
        decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
        and liver dysfunction
      explanation: >-
        Cohort evidence that catatonic stupor carries an increased risk of this
        complication.
  - target: Disseminated intravascular coagulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reported as a systemic complication of catatonic stupor in the same
      cohort.
    evidence:
    - reference: PMID:37039129
      reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        increased risk of various infections (pneumonia, urinary tract infection
        and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
        dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
        decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
        and liver dysfunction
      explanation: >-
        Cohort evidence that catatonic stupor carries an increased risk of this
        complication.
- name: Hyperkinetic and Aberrant-Volitional Output
  biological_scale: ORGANISM
  description: >-
    The hyperkinetic and aberrant-volitional pole — excitement, agitation not
    prompted by external stimuli, stereotypy, mannerism, echolalia and
    echopraxia. Dimensional work identifies these as components that overlap
    with the hypokinetic pole within a single episode, so an entry that modeled
    catatonia as either akinetic or excited would misrepresent the syndrome.
  biological_processes:
  - preferred_term: locomotory behavior
    term:
      id: GO:0007626
      label: locomotory behavior
    modifier: INCREASED
  evidence:
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      catatonia is internally heterogeneous, with hypokinetic, hyperkinetic, and
      aberrant-volitional components that often overlap within the same episode
    explanation: >-
      The dimensional claim that justifies curating hyperkinetic and
      aberrant-volitional features as a distinct but co-occurring output.
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, excitement often co-occurred in these patients suggesting that
      fluctuations in catatonic semiology may be frequent.
    explanation: >-
      Empirical support for within-episode fluctuation between the two poles.
- name: Autonomic Decompensation
  biological_scale: ORGANISM
  description: >-
    Malignant catatonia is catatonia with clinically significant autonomic
    abnormality — disturbance of temperature, blood pressure, heart rate, and
    respiratory rate. It is a life-threatening form of acute brain dysfunction
    and is the principal reason catatonia is a medical emergency rather than
    only a psychiatric one; untreated, it may be fatal. Its phenotypic overlap
    with neuroleptic malignant syndrome is longstanding and unresolved.
  evidence:
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malignant catatonia describes catatonia that presents with clinically
      significant autonomic abnormalities including change in temperature, blood
      pressure, heart rate, and respiratory rate.
    explanation: >-
      Defines the autonomic decompensation this node represents.
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prompt recognition and treatment of catatonia are crucial because malignant
      catatonia may be fatal without treatment.
    explanation: >-
      Records the outcome that makes this node the highest-stakes branch of the
      graph.
phenotypes:
- category: Behavioral
  name: Mutism
  description: >-
    Absence of, or dramatic reduction in, speech. One of the two most prevalent
    signs in the NMDA receptor antibody encephalitis case literature and a core
    diagnostic criterion.
  phenotype_term:
    preferred_term: Mutism
    term:
      id: HP:0002300
      label: Mutism
  evidence:
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent signs were immobility/stupor (70%), mutism (67%),
      excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and
      rigidity (30%).
    explanation: >-
      Quantifies mutism among the most prevalent catatonic signs in a defined
      cohort.
- category: Motor
  name: Akinesia
  description: >-
    Reduction or absence of spontaneous movement, up to akinetic stupor. The
    akinetic presentation is the one in which the GABA-A receptor imaging
    findings were obtained.
  phenotype_term:
    preferred_term: Akinesia
    term:
      id: HP:0002304
      label: Akinesia
  evidence:
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical picture of catatonia ranges from akinetic stupor to severe
      motoric excitement.
    explanation: >-
      Establishes akinetic stupor as a recognized presentation of catatonia.
- category: Motor
  name: Abnormal posturing
  description: >-
    Spontaneous assumption of postures sustained against gravity, and catalepsy
    — a posture induced by an examiner and maintained against gravity.
  phenotype_term:
    preferred_term: Abnormal posturing
    term:
      id: HP:0002533
      label: Abnormal posturing
  evidence:
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent signs were immobility/stupor (70%), mutism (67%),
      excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and
      rigidity (30%).
    explanation: >-
      Reports posturing/catalepsy as an ascertained catatonic sign with its
      frequency in the cohort.
- category: Motor
  name: Motor stereotypy
  description: >-
    Non-goal-directed movement repeated to abnormal frequency, part of the
    hyperkinetic and aberrant-volitional pole.
  phenotype_term:
    preferred_term: Motor stereotypy
    term:
      id: HP:0000733
      label: Motor stereotypy
  evidence:
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent signs were immobility/stupor (70%), mutism (67%),
      excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and
      rigidity (30%).
    explanation: >-
      Reports stereotypies among the ascertained catatonic signs.
- category: Motor
  name: Rigidity
  description: >-
    Increased muscle tone on passive movement, distinct from the waxy
    flexibility in which resistance to repositioning is steady and even.
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent signs were immobility/stupor (70%), mutism (67%),
      excitement (50%), posturing/catalepsy (34%), stereotypies (31%), and
      rigidity (30%).
    explanation: >-
      Reports rigidity among the ascertained catatonic signs.
- category: Behavioral
  name: Negativism
  description: >-
    Resistance to instructions, which may extend to doing the opposite of what
    is asked — an aberrant-volitional rather than purely motor sign.
  phenotype_term:
    preferred_term: Negativism
    term:
      id: HP:0410291
      label: Negativism
  evidence:
  - reference: PMID:37236789
    reference_title: The diagnosis and treatment of catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Negativism (resistance to instructions, which might even entail doing the
      opposite to them)
    explanation: >-
      The DSM-5-TR criterion definition, from the BAP concise guideline's
      summary of diagnostic criteria.
- category: Behavioral
  name: Echolalia
  description: >-
    Repetition of another person's speech; with echopraxia (mimicry of another
    person's movements) these constitute the echophenomena of catatonia.
  phenotype_term:
    preferred_term: Echolalia
    term:
      id: HP:0010529
      label: Echolalia
  evidence:
  - reference: PMID:37236789
    reference_title: The diagnosis and treatment of catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Echolalia (repetition of another person's speech)
    explanation: >-
      The DSM-5-TR criterion definition for echolalia as a catatonic sign.
- category: Behavioral
  name: Facial grimacing
  description: >-
    Grimacing is a listed diagnostic feature and, in periodic catatonia, a
    characteristic long-term residual sign.
  phenotype_term:
    preferred_term: Facial grimacing
    term:
      id: HP:0000273
      label: Facial grimacing
  evidence:
  - reference: PMID:12384773
    reference_title: "Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disorder is characterized by qualitative hyperkinetic and akinetic
      psychomotor disturbances through acute psychotic episodes and debilitating
      symptoms in the long term, with psychomotor weakness, grimacing facial
      movements and apathy.
    explanation: >-
      Reports grimacing facial movements as a persistent feature in the
      periodic-catatonia phenotype.
- category: Behavioral
  name: Agitation
  description: >-
    Agitation that is not prompted by external stimuli, part of the excited
    presentation.
  phenotype_term:
    preferred_term: Agitation
    term:
      id: HP:0000713
      label: Agitation
  evidence:
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical picture of catatonia ranges from akinetic stupor to severe
      motoric excitement.
    explanation: >-
      Establishes severe motoric excitement as a recognized pole of the
      syndrome.
- category: Autonomic
  name: Fever
  description: >-
    Temperature disturbance is one of the autonomic abnormalities defining
    malignant catatonia.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malignant catatonia describes catatonia that presents with clinically
      significant autonomic abnormalities including change in temperature, blood
      pressure, heart rate, and respiratory rate.
    explanation: >-
      Names temperature change among the defining autonomic abnormalities of
      malignant catatonia.
- category: Autonomic
  name: Tachycardia
  description: >-
    Heart-rate disturbance is one of the autonomic abnormalities defining
    malignant catatonia.
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
  evidence:
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malignant catatonia describes catatonia that presents with clinically
      significant autonomic abnormalities including change in temperature, blood
      pressure, heart rate, and respiratory rate.
    explanation: >-
      Names heart-rate change among the defining autonomic abnormalities of
      malignant catatonia.
- category: Respiratory
  name: Pneumonia
  description: >-
    Infection complicating prolonged catatonic immobility, reported alongside
    urinary tract infection and sepsis in a large cohort of patients with
    schizophrenia and catatonic stupor.
  phenotype_term:
    preferred_term: Pneumonia
    term:
      id: HP:0002090
      label: Pneumonia
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased risk of various infections (pneumonia, urinary tract infection
      and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
      dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
      decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
      and liver dysfunction
    explanation: >-
      Names pneumonia among the complications carried by catatonic stupor in the
      cited cohort.
- category: Cardiovascular
  name: Deep venous thrombosis
  description: >-
    Venous thromboembolic complication of sustained immobility. Its
    preventability is why the guideline recommends pharmacological
    thromboprophylaxis in immobile catatonic patients.
  phenotype_term:
    preferred_term: Deep venous thrombosis
    term:
      id: HP:0002625
      label: Deep venous thrombosis
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased risk of various infections (pneumonia, urinary tract infection
      and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
      dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
      decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
      and liver dysfunction
    explanation: >-
      Lists deep vein thrombosis among the complications of catatonic stupor.
- category: Cardiovascular
  name: Pulmonary embolism
  description: >-
    The embolic consequence of immobility-associated venous thrombosis, and one
    of the mechanisms by which non-malignant catatonia can still be fatal.
  phenotype_term:
    preferred_term: Pulmonary embolism
    term:
      id: HP:0002204
      label: Pulmonary embolism
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased risk of various infections (pneumonia, urinary tract infection
      and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
      dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
      decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
      and liver dysfunction
    explanation: >-
      Lists pulmonary embolus among the complications of catatonic stupor.
- category: Musculoskeletal
  name: Rhabdomyolysis
  description: >-
    Skeletal muscle breakdown arising from sustained posturing, rigidity, and
    immobility; it is also the shared feature that complicates the malignant
    catatonia versus neuroleptic malignant syndrome differential.
  phenotype_term:
    preferred_term: Rhabdomyolysis
    term:
      id: HP:0003201
      label: Rhabdomyolysis
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased risk of various infections (pneumonia, urinary tract infection
      and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
      dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
      decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
      and liver dysfunction
    explanation: >-
      Lists rhabdomyolysis among the complications of catatonic stupor.
- category: Hematologic
  name: Disseminated intravascular coagulation
  description: >-
    A recognised systemic complication of catatonic stupor in the cohort
    literature, curated here as a consequence of the hypokinetic state rather
    than of autonomic decompensation specifically.
  phenotype_term:
    preferred_term: Disseminated intravascular coagulation
    term:
      id: HP:0005521
      label: Disseminated intravascular coagulation
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased risk of various infections (pneumonia, urinary tract infection
      and sepsis), disseminated intravascular coagulation, rhabdomyolysis,
      dehydration, deep vein thrombosis, pulmonary embolus, urinary retention,
      decubitus ulcers, cardiac arrhythmia, renal failure, NMS, hypernatraemia
      and liver dysfunction
    explanation: >-
      Lists disseminated intravascular coagulation among the complications of
      catatonic stupor.
genetic:
- name: Chromosome 15q15 periodic catatonia susceptibility locus
  presence: Linkage confirmed in a subset of multiplex families
  relationship_type: SUSCEPTIBILITY
  association: >-
    Periodic catatonia, a familial sub-phenotype with recurrent hyperkinetic
    and akinetic psychomotor episodes, maps to a major susceptibility locus on
    chromosome 15q15, confirmed in a second independent genome scan. No causal
    gene has been established at the locus, and the same study demonstrated
    genetic heterogeneity between families, so this is recorded as a
    susceptibility locus rather than as a catatonia gene.
  evidence:
  - reference: PMID:12384773
    reference_title: "Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we confirm mapping of a major gene locus on chromosome 15q15 in a
      second genome scan in a new set of four multiplex families.
    explanation: >-
      Independent confirmation of the linkage signal in a new family set.
  - reference: PMID:12384773
    reference_title: "Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Analysis of individual families showed that one large family showed
      linkage, whereas two others could be clearly excluded, confirming genetic
      heterogeneity.
    explanation: >-
      The heterogeneity caveat: the locus explains some families and is
      excluded in others, so it cannot be read as a general catatonia gene.
  notes: >-
    Linkage-era evidence. The locus has not been resolved to a gene, and
    subsequent candidate-gene work in the region was negative; treat as
    historical support for familial aggregation in a sub-phenotype rather than
    as an actionable genetic finding.
prevalence:
- population: Clinical samples worldwide (psychiatric and medical settings)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 9000.0
  rate_low: 6900.0
  rate_high: 11700.0
  notes: >-
    Pooled mean of 9.0% across 74 studies (k = 80, n = 110,764), 95% CI
    6.9-11.7%. Heterogeneity was very high (I2 = 98%) with evidence of
    publication bias, so the point estimate should be read as an order of
    magnitude rather than a precise rate.
  evidence:
  - reference: PMID:29140521
    reference_title: "Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mean catatonia prevalence was 9.0% (k = 80, n = 110764; 95% CI = 6.9-11.7,
      I2 = 98%, publication bias P < .01)
    explanation: >-
      The pooled meta-analytic estimate, quoted with its confidence interval and
      heterogeneity statistic.
- population: Worldwide, general population
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 10.0
  notes: >-
    Incidence of approximately 10 per 100,000 person-years, as cited in the BAP
    concise guideline.
  evidence:
  - reference: PMID:37236789
    reference_title: The diagnosis and treatment of catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It has an incidence of ≈10 per 100,000 person-years.
    explanation: >-
      States the incidence figure itself, which is what rate_per_100000 records.
      The source's approximation sign is reproduced verbatim inside the quote so
      that the numeral is carried by the snippet rather than supplied from
      outside it.
- population: Individuals with autism spectrum disorder
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 10400.0
  rate_low: 5800.0
  rate_high: 18000.0
  notes: >-
    Meta-analysis of seven studies comprising 969 individuals with ASD.
  evidence:
  - reference: PMID:34906264
    reference_title: "Catatonia in autism spectrum disorders: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our meta-analysis showed that 10.4% (5.8-18.0 95%CI) of individuals with
      ASD have catatonia.
    explanation: >-
      The pooled prevalence of catatonia within the ASD population.
- population: Published NMDA receptor antibody encephalitis case reports
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 60000.0
  notes: >-
    60% of 189 subjects across 139 case reports met a two-core-sign threshold
    applied retrospectively using the Bush-Francis screening instrument. Case
    reports are a selected literature, so this is an upper-bound estimate for
    the autoimmune subgroup, not a population rate.
  evidence:
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Catatonia was present in 60% of these cases.
    explanation: >-
      The proportion of NMDA receptor antibody encephalitis cases meeting
      catatonia criteria in this systematic review.
diagnosis:
- name: Bush-Francis Catatonia Rating Scale
  description: >-
    The most widely used instrument for ascertaining and quantifying catatonia.
    Its screening component defines the core signs, and the full scale is
    sensitive to change, making it the standard outcome measure for treatment
    response.
  evidence:
  - reference: PMID:8686484
    reference_title: "Catatonia. II. Treatment with lorazepam and electroconvulsive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rating scale has predictive value and displays sensitivity to change
      in clinical status.
    explanation: >-
      Establishes the scale's utility as a quantitative response measure, not
      only a diagnostic checklist.
  - reference: PMID:32070914
    reference_title: "Catatonia in N-methyl-d-aspartate receptor antibody encephalitis: Phenomenological characteristics from a systematic review of case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cases were searched for clinical data in keeping with core catatonic signs
      by applying the screening instrument of the Bush-Francis Catatonia Rating
      Scale.
    explanation: >-
      Demonstrates the screening instrument being used as the ascertainment
      standard in systematic research.
- name: Lorazepam challenge test
  description: >-
    A parenteral lorazepam challenge is used both diagnostically and
    prognostically: a positive response to the initial challenge predicted the
    eventual response to a full lorazepam trial. This is a rare instance of a
    psychiatric test whose predictive validity rests on the same mechanism as
    the treatment.
  evidence:
  - reference: PMID:8686484
    reference_title: "Catatonia. II. Treatment with lorazepam and electroconvulsive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A positive response to an initial parenteral challenge predicted final
      lorazepam response, as did length of catatonic symptoms prior to treatment.
    explanation: >-
      The prospective evidence that the challenge test predicts treatment
      response.
treatments:
- name: Lorazepam
  description: >-
    A benzodiazepine positive allosteric modulator at the GABA-A receptor and
    the first-line treatment for catatonia, sometimes required in very high
    doses. In the defining prospective study, catatonic signs resolved in 16 of
    21 patients (76%) who completed a lorazepam trial. The near-immediate
    response of akinesia and anxiety to lorazepam is also the clinical
    observation that motivated the GABA-A receptor hypothesis.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lorazepam
      term:
        id: CHEBI:6539
        label: Lorazepam
  target_mechanisms:
  - target: Cortical GABA-A Receptor-Mediated Inhibition Deficit
    treatment_effect: RESTORES
    description: >-
      Positive allosteric modulation at the benzodiazepine site increases
      GABA-A receptor-mediated chloride conductance, restoring the inhibitory
      tone that is deficient at this node. The same receptor population imaged
      by iomazenil SPECT is the drug's binding site, which is what makes this a
      mechanistically specific rather than symptomatic treatment.
    evidence:
    - reference: PMID:10486389
      reference_title: "Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Catatonia is a psychomotor syndrome with concomittant akinesia and
        anxiety which both respond almost immediately to benzodiazepines such as
        lorazepam.
      explanation: >-
        Links the drug's effect directly to the receptor population this node
        describes.
  evidence:
  - reference: PMID:8686484
    reference_title: "Catatonia. II. Treatment with lorazepam and electroconvulsive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 16 of 21 patients (76%) who received a complete trial of lorazepam (11
      with initial intravenous challenge), catatonic signs resolved.
    explanation: >-
      The prospective, quantitatively monitored response rate underpinning
      first-line status.
  - reference: PMID:37236789
    reference_title: The diagnosis and treatment of catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      First-line treatment comprises benzodiazepines and/or electroconvulsive
      therapy. The benzodiazepine of choice is lorazepam, which is sometimes
      used in very high doses.
    explanation: >-
      Current guideline statement of first-line status and the drug of choice.
- name: Electroconvulsive therapy
  description: >-
    ECT is first-line alongside benzodiazepines and is the treatment of choice
    for catatonia refractory to benzodiazepines and for malignant catatonia,
    where delay is life-threatening. In the defining prospective study, all
    four patients who failed lorazepam responded promptly to ECT. Its mechanism
    is not receptor-specific; it is curated here as modulating the distributed
    network node rather than any single neurochemical route.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: electroconvulsive therapy
    term:
      id: NCIT:C93303
      label: Electroconvulsive Therapy
  target_mechanisms:
  - target: Distributed Psychomotor Network Destabilization
    treatment_effect: MODULATES
    description: >-
      ECT acts on the destabilized network as a whole rather than on a defined
      molecular target, which is consistent with its efficacy in cases that do
      not respond to GABA-A-directed treatment.
    evidence:
    - reference: PMID:8686484
      reference_title: "Catatonia. II. Treatment with lorazepam and electroconvulsive therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Four patients failing lorazepam responded promptly to ECT.
      explanation: >-
        Efficacy in benzodiazepine non-responders is the clinical evidence that
        ECT acts beyond the GABA-A node.
  evidence:
  - reference: PMID:8686484
    reference_title: "Catatonia. II. Treatment with lorazepam and electroconvulsive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is concluded that lorazepam and ECT are effective treatments for catatonia.
    explanation: >-
      The study's own summary conclusion on efficacy.
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Catatonia typically improves with benzodiazepines and treatment of its
      underlying psychiatric or medical conditions, with electroconvulsive
      therapy reserved for catatonia refractory to benzodiazepines or for
      malignant catatonia.
    explanation: >-
      Defines the two indications that position ECT relative to
      benzodiazepines.
- name: Treatment of the underlying condition
  description: >-
    Because catatonia is a convergence syndrome, treating the upstream
    liability is part of definitive management rather than an adjunct — most
    consequentially, immunotherapy in autoimmune encephalitis and withdrawal of
    a precipitating dopamine antagonist. Multidisciplinary working between
    psychiatrists and physicians is frequently required.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Heterogeneous Upstream Liability
    treatment_effect: INHIBITS
    description: >-
      Removing or treating the upstream liability addresses the entry point to
      the mechanism rather than its downstream expression.
    evidence:
    - reference: PMID:35861966
      reference_title: "Malignant Catatonia: A Review for the Intensivist."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Catatonia typically improves with benzodiazepines and treatment of its
        underlying psychiatric or medical conditions
      explanation: >-
        States that treatment of the underlying condition is part of what
        resolves catatonia.
  evidence:
  - reference: PMID:37236789
    reference_title: The diagnosis and treatment of catatonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Multidisciplinary working between psychiatrists and physicians is often
      essential.
    explanation: >-
      Guideline statement reflecting that the upstream cause is frequently
      medical rather than psychiatric.
- name: Amantadine and memantine
  description: >-
    Uncompetitive NMDA receptor antagonists used as second-line pharmacotherapy
    when benzodiazepines fail or are not tolerated. Amantadine additionally
    enhances central dopamine release and delays synaptic dopamine reuptake,
    which is the proposed reason it suits a syndrome hypothesised to involve
    hypodopaminergic tone. The supporting literature is case reports and case
    series rather than trials, so this is curated as a mechanistically
    motivated second-line option, not an established one.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amantadine
      term:
        id: CHEBI:2618
        label: amantadine
    - preferred_term: memantine
      term:
        id: CHEBI:64312
        label: memantine
  target_mechanisms:
  - target: Glutamatergic NMDA Receptor Perturbation and Neuroinflammation
    treatment_effect: MODULATES
    description: >-
      Uncompetitive NMDA receptor antagonism is proposed to rebalance, rather
      than simply suppress, the NMDA receptor perturbation this node describes —
      acting on prefrontal GABA-A parvalbumin interneurons and on striatal NMDA
      signalling within the cortico-striato-thalamo-cortical circuitry.
    evidence:
    - reference: PMID:37039129
      reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The NMDA receptor antagonists, amantadine and memantine, may reset the
        problems related to reduced dopamine and GABA in the CSTC circuitries
      explanation: >-
        States the proposed mechanism by which these agents act on the NMDA
        receptor perturbation curated at this node.
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Medications such as amantadine and memantine serve as uncompetitive
      antagonists of the NMDA receptor and thus may be helpful in patients with
      catatonia.
    explanation: >-
      Guideline statement placing both agents in the catatonia treatment
      repertoire, with the hedged wording preserved.
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Amantadine as monotherapy often abolished catatonia after a few doses.
    explanation: >-
      Reports the observed response, but the underlying evidence is a systematic
      review of 11 articles describing 18 cases, so it supports a signal rather
      than an established effect size — hence PARTIAL.
  notes: >-
    Curated from the BAP consensus guideline's own summary of the case-report
    and case-series literature (18 amantadine cases across 11 articles, plus
    later additions). No controlled trial evidence exists for either agent in
    catatonia.
- name: Avoidance of antipsychotic medication
  description: >-
    Antipsychotic exposure can both induce and worsen catatonia, and catatonia
    is itself a risk factor for neuroleptic malignant syndrome, so antipsychotic
    use in an actively catatonic patient is a recognised hazard. The guideline
    describes this as one of the most controversial areas of catatonia
    management rather than an absolute prohibition — antipsychotics may still be
    indicated for an underlying psychotic illness once catatonia has resolved.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: avoidance of contraindicated medications
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Reduced Striatal Dopaminergic Transmission
    treatment_effect: INHIBITS
    description: >-
      Withholding dopamine antagonists removes an avoidable driver of the
      striatal dopaminergic hypofunction curated at this node — the same
      exposure that defines antipsychotic-induced catatonia and that anchors the
      malignant-catatonia versus neuroleptic malignant syndrome differential.
    evidence:
    - reference: PMID:37039129
      reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antipsychotic medications can induce catatonia
      explanation: >-
        States that the drug class can cause the mechanism this node describes,
        which is what makes withholding it mechanistically directed rather than
        merely cautious.
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in some studies of catatonia, the use of antipsychotics has been
      associated with poor outcomes
    explanation: >-
      Outcome evidence behind the avoidance recommendation, quoted with the
      guideline's own hedge ("in some studies").
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The use of antipsychotics is one of the most controversial areas in
      catatonia management
    explanation: >-
      Records that the guideline frames this as contested rather than settled,
      which is why the entry curates avoidance without asserting an absolute
      contraindication.
differential_diagnoses:
- name: Neuroleptic malignant syndrome
  description: >-
    Malignant catatonia and neuroleptic malignant syndrome share precipitants
    (dopamine antagonist exposure), an overlapping motor phenotype, and
    autonomic instability. Whether they are one entity or two has been debated
    for decades and is not settled here.
  distinguishing_features:
  - NMS is defined by a temporal relationship to dopamine-antagonist exposure, whereas malignant catatonia may arise without it.
  - In practice the distinction is often retrospective, and treatment converges on withdrawal of the offending agent, supportive care, and ECT.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      malignant catatonia/neuroleptic malignant syndrome.
- name: Delirium
  description: >-
    Delirium and catatonia can co-occur, and catatonia comorbid with delirium
    may respond less well to standard treatment.
  distinguishing_features:
  - Delirium is defined by fluctuating attention and awareness; catatonia by the psychomotor sign cluster.
  - Their coexistence is a recognized clinical problem rather than a diagnostic error.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      delirium.
- name: Akinetic mutism and abulia
  description: >-
    Both present with reduced speech and movement without the fuller catatonic
    sign cluster.
  distinguishing_features:
  - Catalepsy, waxy flexibility, negativism, and echophenomena favor catatonia.
  - A response to a parenteral lorazepam challenge favors catatonia.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      abulia/akinetic mutism.
- name: Late-stage Parkinson disease
  description: >-
    Shares hypokinesia, rigidity, and reduced verbal output with the akinetic
    presentation of catatonia; the shared striatal dopaminergic substrate is
    the basis of the proposal that catatonia be considered a psychiatric
    parkinsonism.
  distinguishing_features:
  - Parkinson disease shows a progressive course with rest tremor and levodopa responsiveness.
  - Catatonia is typically episodic and benzodiazepine-responsive.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      late-stage Parkinson's disease.
- name: Locked-in syndrome
  description: >-
    Preserved awareness with near-total loss of voluntary movement can be
    mistaken for stupor.
  distinguishing_features:
  - Locked-in syndrome follows a structural brainstem lesion demonstrable on imaging.
  - Vertical eye movement and blinking are spared in locked-in syndrome.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      locked-in syndrome.
- name: Serotonin syndrome
  description: >-
    Autonomic instability with altered mental status and neuromuscular
    abnormality overlaps with malignant catatonia.
  distinguishing_features:
  - Serotonin syndrome follows serotonergic drug exposure.
  - Clonus and hyperreflexia are characteristic, rather than catalepsy and negativism.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      serotonin syndrome.
- name: Stiff-person syndrome
  description: >-
    Autoimmune rigidity with axial and limb muscle stiffness can be mistaken for
    catatonic rigidity and posturing, and both may respond partially to
    benzodiazepines — which removes the lorazepam challenge as a discriminator.
  distinguishing_features:
  - Stiff-person syndrome is associated with anti-GAD65 (or anti-amphiphysin) antibodies and continuous motor unit activity on EMG.
  - Stiffness is stimulus-sensitive and painful, without the echophenomena, negativism, or mutism of the catatonic sign cluster.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      stiff-person syndrome.
- name: Akathisia
  description: >-
    Antipsychotic-associated motor restlessness overlaps with the hyperkinetic
    and agitated pole of catatonia, and the two share an antipsychotic-exposure
    history.
  distinguishing_features:
  - Akathisia is dominated by a subjective sense of inner restlessness that the patient can usually report.
  - Movement in akathisia is purposeful relief-seeking, rather than the non-goal-directed stereotypy and mannerism of catatonia.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      akathisia.
- name: Major neurocognitive disorders
  description: >-
    Advanced dementia can present with reduced speech, reduced spontaneous
    movement, and apparent negativism. Catatonia may also occur on top of a
    major neurocognitive disorder rather than instead of it.
  distinguishing_features:
  - Major neurocognitive disorders follow a chronic progressive course, whereas catatonia is typically episodic with a definable onset.
  - Catalepsy, waxy flexibility, and echophenomena are not features of dementia itself.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      major neurocognitive disorders.
- name: Mania
  description: >-
    Manic excitement overlaps with the hyperkinetic pole of catatonia, and
    excited catatonia has historically been conflated with mania.
  distinguishing_features:
  - Manic agitation is goal-directed and accompanied by elevated mood, pressured speech, and reduced need for sleep.
  - Catatonic excitement is non-goal-directed and co-occurs with hypokinetic signs within the same episode.
  evidence:
  - reference: PMID:40368005
    reference_title: "Catatonia: American Psychiatric Association Resource Document."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abulia/akinetic mutism, delirium, major neurocognitive disorders,
      locked-in syndrome, late-stage Parkinson's disease, stiff-person syndrome,
      akathisia, mania, malignant catatonia/neuroleptic malignant syndrome,
      autoimmune encephalitis, and serotonin syndrome
    explanation: >-
      The APA Resource Document enumerates the catatonia differential, including
      mania.
discussions:
- discussion_id: catatonia_no_unified_mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Distributed Psychomotor Network Destabilization
  prompt: >-
    Is there a single mechanism or biomarker that accounts for catatonia across
    its psychiatric, neurologic, autoimmune, and medical contexts, or is the
    convergent-network account the correct final level of explanation?
  rationale: >-
    This is the central open question of the entry and the reason the
    pathophysiology is curated as several parallel routes into one hub rather
    than as a single chain. The literature is explicit that no single biomarker
    or unified mechanism fully accounts for catatonia across contexts, and that
    the neurochemical evidence describes interacting rather than
    single-transmitter disturbance. Resolving it matters practically: if the
    convergent-network account is correct, subtype-sensitive treatment
    selection is the achievable goal and a universal catatonia biomarker is not.
  proposed_experiments:
  - experiment_id: exp_catatonia_acute_state_multimodal_cohort
    name: Prospective acute-state multimodal phenotyping across upstream causes
    description: >-
      Recruit an acute-state catatonia cohort stratified by upstream cause
      (mood disorder, schizophrenia-spectrum, autoimmune encephalitis, medical
      or drug-induced) and acquire the same multimodal battery in every stratum:
      resting-state and emotional-task fMRI, GABA-A receptor imaging, striatal
      dopaminergic imaging, CSF and serum neuronal autoantibodies, and
      dimensional Bush-Francis and Northoff scale scoring. The discriminating
      test is whether the network signature is shared across strata while the
      neurochemical signature differs by stratum — the prediction of the
      convergent model — or whether each stratum has its own network signature.
  evidence:
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No single biomarker or unified mechanism fully accounts for catatonia
      across contexts.
    explanation: >-
      The explicit statement of the gap this discussion records.
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Future progress will depend on dimensional phenotyping, multimodal
      biomarker integration, and subtype-sensitive treatment research.
    explanation: >-
      The authors' own statement of what would close the gap, which the
      proposed experiment operationalizes.
- discussion_id: catatonia_sampling_and_acute_state_bias
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Distributed Psychomotor Network Destabilization
  - pathophysiology#Orbitofrontal Emotional-Motor Processing Dysfunction
  prompt: >-
    How much of the imaging evidence for the distributed-network model is an
    artifact of studying schizophrenia-spectrum patients in the post-acute
    state rather than catatonia in the acute state across its full diagnostic
    range?
  rationale: >-
    The two limitations compound. The multimodal MRI evidence comes from a
    schizophrenia-spectrum sample, and the orbitofrontal fMRI evidence comes
    from post-acute patients whose authors explicitly interpret the finding as
    a trait marker of predisposition rather than a state correlate. A network
    signature derived under both constraints may describe the vulnerability of
    one diagnostic group rather than the mechanism of the acute syndrome. This
    is a limit on how causally the hub node may be read, and it is recorded
    rather than smoothed over.
  evidence:
  - reference: PMID:42431537
    reference_title: "Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      key limitations remain, including the overrepresentation of
      schizophrenia-spectrum samples and limited acute-state data
    explanation: >-
      Names both sampling limitations directly.
  - reference: PMID:15279056
    reference_title: "Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Because we investigated postacute patients, orbitofrontal cortical
      alterations may be interpreted as a trait marker predisposing for
      development of catatonic syndrome
    explanation: >-
      A worked instance of the acute-state limitation, stated by the original
      authors.
- discussion_id: catatonia_evidence_quality_ceiling
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Distributed Psychomotor Network Destabilization
  prompt: >-
    Can treatment recommendations for catatonia be raised above their current
    evidence ceiling, given that first-line therapy rests on observational
    studies and case series rather than randomized trials?
  rationale: >-
    Catatonia is unusual in that its first-line treatments are both effective
    and poorly evidenced by contemporary standards. The BAP consensus guideline
    states plainly that clinical trials were uncommon and that its
    recommendations are mainly informed by small observational studies, case
    series, and case reports. The 76% lorazepam response rate curated in this
    entry comes from an open, non-randomized prospective protocol in 28
    patients. Any downstream use of this entry for therapeutic inference should
    carry that ceiling with it.
  evidence:
  - reference: PMID:37039129
    reference_title: "Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical trials were uncommon, and the recommendations in this guideline
      are mainly informed by small observational studies, case series and case
      reports, which highlights the need for randomised controlled trials and
      prospective cohort studies in this area.
    explanation: >-
      The guideline's own statement of the evidence ceiling.
- discussion_id: catatonia_malignant_vs_nms
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Autonomic Decompensation
  - pathophysiology#Reduced Striatal Dopaminergic Transmission
  prompt: >-
    Are malignant catatonia and neuroleptic malignant syndrome one entity with
    two names, or two entities that share a striatal dopaminergic substrate?
  rationale: >-
    The two syndromes share precipitants, an overlapping motor phenotype,
    autonomic instability, and a treatment pathway that converges on
    withdrawing the offending agent and ECT. The striatal-dopamine hypothesis
    supplies a mechanism that would unify them. Against unification, malignant
    catatonia occurs without dopamine-antagonist exposure. The question is
    recorded as an open controversy because the entity distinction currently
    rests on exposure history rather than on any mechanistic discriminator.
  evidence:
  - reference: PMID:40966690
    reference_title: Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, there are close epidemiological relationships between
      depression and Parkinson's disease, and between catatonia and neuroleptic
      malignant syndrome.
    explanation: >-
      Records the epidemiological relationship that a shared-substrate account
      would explain.
  - reference: PMID:35861966
    reference_title: "Malignant Catatonia: A Review for the Intensivist."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malignant catatonia describes catatonia that presents with clinically
      significant autonomic abnormalities including change in temperature, blood
      pressure, heart rate, and respiratory rate.
    explanation: >-
      Supplies the definition of the entity on the catatonia side of the
      controversy.
- discussion_id: catatonia_hpo_term_gap
  kind: CURATION_TODO
  status: OPEN
  attaches_to:
  - pathophysiology#Hypokinetic Psychomotor Output
  prompt: >-
    HPO has no term for catatonia, or for stupor, catalepsy, or waxy
    flexibility. Should a new-term request be filed, and until then how should
    the syndrome be bound in entries where it appears as a phenotype?
  rationale: >-
    Searched HPO for catatonia, stupor, catalepsy, and waxy flexibility on
    2026-08-14: none exists. HPO does carry the component signs used in this
    entry (Mutism HP:0002300, Abnormal posturing HP:0002533, Negativism
    HP:0410291, Motor stereotypy HP:0000733, Echolalia HP:0010529, Facial
    grimacing HP:0000273, Akinesia HP:0002304, Rigidity HP:0002063). MONDO does
    have catatonia (MONDO:0800105), which is why this is curated as a disease
    entry rather than as a disease-like phenotype module — the module family for
    disease-like phenotypes requires both an HP and a MONDO identifier. The
    practical consequence is that a disorder in which catatonia occurs cannot
    bind it as a single phenotype term and must either enumerate the component
    signs or leave the phenotype unbound, as the Schizophrenia entry currently
    does. An HPO new-term request would close this.
  notes: >-
    Upstream ontology gap, not a dismech bug. Recorded here so the decision is
    auditable rather than rediscovered.
notes: >-
  Scope decision (issue #6531). Catatonia is curated as a standalone Disease
  entry anchored on MONDO:0800105 rather than as a mechanism module, for three
  reasons. First, the disease-like-phenotype module family requires a concept
  carrying both an HP and a MONDO identifier, and HPO has no catatonia term
  (see the catatonia_hpo_term_gap discussion). Second, a mechanism module
  asserts a conserved causal chain that conforming disorders duplicate, and the
  defining feature of the current catatonia literature is that no such
  conserved chain is established — a module would assert more than the evidence
  supports, whereas competing mechanistic_hypotheses inside a disease entry
  express the heterogeneity honestly. Third, catatonia is a MONDO disease
  concept in its own right, which is the unit the psychiatric curation SOP
  assigns one entry to. If the convergent-network model consolidates, promoting
  the hub chain to a module and having Schizophrenia, Autoimmune_Encephalitis,
  Anti-NMDA_Receptor_Encephalitis and others declare conforms_to would be the
  natural follow-up.

  Cross-entry follow-up not done here: Schizophrenia carries a Catatonia
  phenotype with no phenotype_term binding, and Autoimmune_Encephalitis and
  Anti-NMDA_Receptor_Encephalitis mention catatonia only in prose. Wiring those
  entries to this one is deliberately left as separate work so this entry can be
  reviewed on its own.

  Evidence-quality note: the treatment evidence here is the best available but
  is observational (see the catatonia_evidence_quality_ceiling discussion). The
  striatal-dopamine node rests on a hypothesis-level synthesis about psychomotor
  retardation across disorders rather than on catatonia-specific measurement,
  and its evidence is marked PARTIAL accordingly.